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Chapter 1: Preface 
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After finishing my master studies in Economics I started to work as a Health Economic 
consultant for an international company located in Loerrach / Germany. After some months 
working there I started to think about a cumulative PhD thesis in the area of applied Discrete 
Choice Analysis and some issues I found in the economic evaluation methods.  
I have to thank Prof. Peter Zweifel that he was that flexible to accept me as an external PhD 
student in April 2005. After some discussions with Rito Bergemann I wrote, together with him, a 
paper about possible biases in the current Cost-Effectiveness methods due to a possible wrong 
use of the discount rate (Chapter 1). At the same time Marcos Memran from New York, also a 
consultant, suggested that he can support me in collecting my own dataset for a discrete choice 
analysis in the US. I started to develop the questionnaire based on my knowledge I build due to 
extensive literature reading and my consulting work I have done with some of the biggest 
pharmaceutical companies. In March 2006 I received the whole dataset and I started to analyze 
these regarding preferences and willingness-to-pay (chapters 2 and 3). Additionally I analyzed 
the dataset regarding an issue called the “learning effect” in discrete choice analysis (chapter 4). 
During discussions at the ISPOR (International Society for Pharmacoeconomics and Outcomes 
Research) congress 2005 in Florence about budget impact modeling, a relatively new feature in 
the economic evaluation tools, I had the idea that early retirement should have an influence on 
the decision making of a new pharmaceutical drug based on a budget impact analysis. I 
developed a theoretical framework for that and tested it in a hypothetical example in the diabetes 
area (chapter 5). 
My sincere thanks also go to other former colleagues of mine: Luca Morlotti, who was always 
available for discussions and criticisms; Elvira Müller for her reviews and the time she gave me 
to do all my PhD courses within one year; Monika Neumann who did the formatting of my 
papers; Heather Falvey, Per-Olov Johansson and Mikael Svensson for their reviews of different 
papers. 
Due to the fact that the biggest gratitude is always mentioned at the end, I want to thank my girl 
friend and future wife, Sabrina Wrobel, for allowing me to always count on her full support and 
encouragement during this endeavor. She had to bear the biggest burden due to the hours I 
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spent with my books, papers, datasets and discussions in nearly each second of my (rare) 
leisure time. However she always supported me without any ifs or buts. 
 
 
Lörrach, November 2006       Stefan Walzer 
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Chapter 2: Introduction 
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The five essays offered in this monograph cover three topics in economic evaluations: The first 
essay is a theoretical investigation of a new cost-effectiveness analysis approach by using a 
variable discount rate over time for long-term and chronic diseases such as diabetes. The 
second and third essays address an empirical discrete choice analysis by showing first the 
preferences and then the willingness-to-pay for various characteristics of an asthma treatment 
for caregivers with children aged 4 years and younger. The fourth essay is an analysis whether a 
so-called learning effect can be proven within an empirical discrete choice approach.  
The fifth essay, finally, belongs to the realm of budget impact modeling, a relatively new tool in 
the economic evaluation. It develops a theoretical model explaining the impact of early 
retirement on the decision-making based on such a model. 
All five essays can be placed in the same region of economics. They are all based in the 
economic evaluations whereas different approaches were used or more developed. The cost-
effectiveness analysis is widely used for the submission of drug and intervention/device 
appraisals for reimbursement or funding and/or price negotiations in various countries such as 
UK, Canada, Italy, Sweden and others. The conjoint analysis is more applied to derive the 
utilities and preferences of (potential) consumers. Furthermore the results of such a study, 
especially when using a willingness-to-pay approach could also be applied to a cost-benefit 
analysis. The budget impact approach was introduced to analyze the affordability of new 
drugs/interventions/devices for countries with a given budget. Usually budget impact analysis 
complements a cost-effectiveness or cost-benefit analysis. The five essays here are following a 
similar pathway. All five essays could be seen as a flow of a usual evaluation of a new 
drug/intervention/device. First a cost-effectiveness analysis, applying the new approach, could 
be performed before demand estimation and the drivers of demand are analyzed by applying a 
conjoint analysis. The willingness-to-pay of individuals is estimated whereas the potential bias by 
a learning effect could be neglected according to the findings here. Finally the budget impact 
analysis could complement the whole story by showing a third party payer the influence of the 
new drug/intervention/device on their (fixed) budget. 
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In the first essay the current approach of cost-effectiveness analysis especially for long-term 
diseases is criticized and a new approach is suggested: In cost-effectiveness analyses 
consensus exists among health economists regarding adjustment of discount rates with a 
constant and equal inflation rate for the time horizon considered in the analysis. This general 
assumption can cause biased results when different yearly inflation rates exist for the time 
horizon of the analysis. Adjustment of the discount rate does not result in the same cost-
effectiveness value as the general economic approach where the inflation rate and the non-
adjusted discount rate are taken into account. In our manuscript the adjusted-discount rate 
approach is compared with the general economic approach, where inflation rate and unadjusted 
discount rates are employed. Furthermore the potential for bias when assuming constant and 
equal inflation rates for each year is compared with a flexible inflation rate approach. 
Comparisons of these methods are explored theoretically and then applied to a hypothetical 
cohort of patients with myocardial infarction. 
 
Essays two to four are all analysis run with caregivers having children suffering from asthma. 
Nearly 5 million children in the United States are affected by asthma, which is more than 5 
percent of the population younger than 18 years. There are several effective drugs that relieve 
the symptoms of asthma and others are currently being developed but even when these 
medications are prescribed, they may be underutilized because parents fear the possibility of 
adverse events. Up to now there is no knowledge, which are the main drivers of caregiver’s 
preferences for a safe and effective medication for pre-school children in general. For this 
reason a preference study using a conjoint analysis was set up. From these results willingness-
to.-pay analyses were also conducted to separate the charcteristics for which caregivers are 
mostly willing to pay. The overall result was that the most important feature for an asthma 
treatment, in this study, was the attribute episode free days. The purpose of essay four was to 
evaluate, using conjoint analysis and utility rating scale from 0 to 10 separately, asthma patients’ 
preferences for different aspects of asthma treatment and the possible existence of learning 
effects. The respondents were asked, after they decided which treatment options they have 
chosen, how they would rate the importance (in terms of utility) of their decision. It turns out that 
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the influence of the product attributes on the score rating was statistically not significant. Even in 
the three scenarios where it could be shown that the attributes have a statistically significant 
influence two of the four attributes showed collinearity between each other. Findings of the 
correlation analyzes could be interpreted as a learning effect between the utility score and the 
scenario decisions made before. 
The final essay was conducted to contribute to current discussions about budget impact 
modeling. For this two different approaches for the impact of a new pharmaceutical product were 
analyzed: firstly considering the impact on annual health care expenditures only and secondly 
additional inclusion of lost insurance premiums due to possible early retirement in patients with 
chronic diseases. The budget impact was calculated from two different perspectives: a) the 
impact on health care expenditures and b) on expenditures as well as on health insurance 
revenues due to premiums. Results in terms of reimbursement decisions of the budget impact 
analysis varied depending on the assumptions made for the insurance premiums, costs and 
early retirement rate.  
Note that Rito Bergemann co-authored chapter 3 and Peter Zweifel co-authored chapter 5. 
Chapters 3 and 6 are under review with the Journal of Medical Decision Making. Chapter 5 was 
accepted for publication in the Journal of Therapeutics and Clinical Risk Management as well as 
chapter 4. Finally chapter 7 is under review for publication in the Journal of Vascular Health and 
Risk Management. 
 
Stefan Walzer 
       Lörrach, November 2006 
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Chapter 3: Cost-effectiveness: Biased results among 
current analyses? 
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Abstract 
Background: In cost-effectiveness analyses consensus exists among health economists 
regarding adjustment of discount rates with a constant and equal inflation rate for the time 
horizon considered in the analysis. This general assumption can cause biased results when 
different yearly inflation rates exist for the time horizon of the analysis. Adjustment of the 
discount rate does not result in the same cost-effectiveness value as the general economic 
approach where the inflation rate and the non-adjusted discount rate are taken into account.  
 
Methods: The adjusted-discount rate approach is compared with the general economic 
approach, where inflation rate and unadjusted discount rates are employed. Furthermore the 
potential for bias with assuming constant and equal inflation rates for each year is compared 
with a varied inflation rate approach. Comparisons of these methods are explored and then 
applied to a hypothetical cohort of patients with myocardial infarction. The accepted, current 
cost-effectiveness analyses, which are not taking yearly varying inflation rates into account, 
produce biased results. This finding is proved by mathematical derivation. Additionally it is 
shown that the cost differences between the current approach and the suggested approach 
(including yearly-varying inflation rates) could add up to approximately 30% of total costs 
incurred during time horizon of 10 years for a hypothetical comparison.  
 
Conclusions: When conducting cost-effectiveness analysis in chronic diseases, unadjusted 
discount rates, including not constant inflation rates should be employed given the extended 
time horizon. Due to the fact that inflation rates are difficult to forecast, past values are 
recommended as potential estimators. 
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Introduction 
The importance of economic evaluations in health technology assessments and submission 
processes for new pharmaceutical products is continually increasing worldwide. Cost-
effectiveness analyses, for example, are essential for the National Institute for Clinical 
Excellence (NICE) in the United Kingdom submission process (1). NICE evaluates and update 
their guidelines regularly according to new knowledge and methods which reflects the more 
current analyses and methodological techniques. Other health authorities, including CCOHTA in 
Canada (2), PBAC in Australia (3) and others (4-7), also strongly recommend the use of 
economic evaluations (cost-effectiveness, cost-utility, cost-benefit and net-health-benefit 
analyses) in their submission guidelines. 
Guidelines for economic evaluations have been published and updated in recent years to enable 
the comparability of different published studies (1,2,8,9).  
 
Health economists generally adjust the discount rate by the yearly inflation rate and assume 
constant and equal yearly inflation rates (10). However, in the real-world, the inflation rate of 
health care costs can vary in time, as can be seen in figure 1, where the CPI of the US Medical 
Services is shown (9). This issue is of paramount importance in health care systems that enforce 
stringent costs and price controls. 
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Figure 1  Price changes for different cost centers related to the treatment of a myocardial infarction (9) 
 
According to general economic theory, future costs and effects are calculated to include the 
increase in these values and the corresponding unadjusted discount rate (11). Reasons for the 
economic discounting are the myopia of the subjects, which reflects the expectations of future 
cost increases (i.e. inflation rate) and the preference of the present to the future (12). This 
behaviour just reflects the risk aversion of subjects for uncertainty. 
Current economic evaluations typically adjust the discount rate with a constant and equal yearly 
inflation rate for both costs and effects (1,10). In diseases with short-term outcomes (e.g. 
influenza), this approach is valid given the brief time horizon; however for chronic diseases like 
diabetes, where even a lifetime view could be taken, constant yearly inflation rates are not a 
reflection of reality. 
 
The present paper explores the difference in results by comparing the current cost-effectiveness 
approach and an unadjusted discount rate and the yearly inflation rate approach. Furthermore, 
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the influence of varying yearly inflation rates on cost-effectiveness results is analyzed. Finally, a 
hypothetical example is given to present recommendations for health economists in the future.  
 Stefan Walzer – 5 Essays in Health Economics 17 
Methods 
Cost-effectiveness – Theoretical approach 
A cost-effectiveness analysis compares the mean cost-effectiveness of a new health care 
intervention with the mean cost-effectiveness of an old intervention (12). The analysis is based 
on the accumulation of costs (either direct or indirect and measured in the given currency) and 
effects (measured in this example as quality-adjusted life years, QALYs). 
Let 
Cj = Mean total costs of treatment j  
Ej = Mean total effects of treatment j  
d = Yearly discount rate; 0 < d < 1 
in = Yearly varying inflation rate; 0 < in < 1 
ic = Constant and equal yearly inflation rate; 0 < ic < 1 
r = Yearly discount rate, where the constant and equal yearly inflation rate ic was  
      subtracted (d-ic = r < d)  
n = time horizon; n=1, … , N 
j = A if new treatment 
  = B if old treatment 
The currently used incremental cost-effectiveness ratio approach (ICERd) can then be written as 
the following (eq 1): 
 
(eq 1)   
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+
=
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The effects for treatments A, Ead, and B, Ebd, (i.e. Ead ≠ Ebd) are different. Whereas the two 
different effects are assumed to be the same for both approaches, i.e. that Ead = Eay and Ebd = 
Eby. Given this assumption, the effects need not be discounted since results would remain 
equivalent. Additionally health economists have agreed not to inflate effects, which will not be 
done in this analysis either (12,13). 
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When assuming a yearly inflation rate in for a cost-effectiveness analysis, equation (eq 1) can be 
rewritten as follows: 
 
 (eq 2)   
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For the first scenario it is assumed that the yearly inflation rates are constant and equal over 
time, i.e. that in = ic. Obviously the incremental cost-effectiveness including the yearly inflation 
rate should be different in comparison to the cost-effectiveness approach, which adjusts the 
discount rate with a constant and equal inflation rate. This statement will be proved by assuming 
the same effects and hence also the same event rates for the two treatment arms A and B for 
the two approaches (eq 3). 
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The left side of the equation is the cost-effectiveness including the yearly inflation rates (ICERy) 
and the right side is the cost-effectiveness approach adjusting the discount rate for the inflation 
rate (ICERd). By assuming that the adjusted discount rate r is the difference between the 
nominal discount rate d (including time preferences) and the expected inflation rates ic equation 
(eq 3) is reformulated as: 
 
(eq 4)   
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To simplify the comparison equation (eq 4) is first multiplied with the effects and then with the 
remaining denominator of the right-hand side. Additionally in and ic are set to ic due to the fact 
that in = ic. 
 
(eq 5)   
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After calculations equation (eq 5) results in equation (eq 6): 
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When using the Taylor series the following expression can be computed (Appendix 1): 
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Hence the difference between the current approach and the unadjusted discounted approach is 
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As previously discussed, in the real-world setting, yearly inflation rates vary; therefore 
equation (eq 4) is re-expressed as follows: 
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(eq 9)   
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Via the Taylor series (Appendix 2), the following is the difference between the two approaches 
(eq 10): 
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Equations (eq 8) and (eq 10) prove that the cost-effectiveness ratio is not the same as the 
current approach for nearly all circumstances when the yearly inflation rate, whether constant or 
not, is included. The current approach leads to the same results as the approach suggested 
here in the following situations: 
• Costs for treatment A (Ca) are equal to costs of treatment B (Cb) 
• The statement (1+d+dic-ic
2) and (1+d+ic+in+din-inic) is equal to zero, which means that 
the discount rate arguments and the inflation rate arguments are equal to each other, 
hence the discount rate is not taking the uncertainty into account 
• The time horizon n tends towards zero (which is not defined in the cost-effectiveness 
analysis) 
 
Cost effectiveness – Case example  
In order to compare the inflated cost-effectiveness approach with the accepted approach the 
hypothetical event rates for a myocardial infarction are assumed. 
The non-cumulative, hypothetical number of events is taken per 1,000 patients at baseline. 
These events were assumed to occur in a patient with progressive disease (e.g. type 2 
diabetes). Treatment costs for the “old” treatment B was assumed to be 40 US dollars per year, 
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whereas the “new” and innovative treatment A costs 80 US dollars per year. The cost of a (non-
fatal) myocardial infarction was 8,876 US dollars. Cost data for the event was derived from a 
cost utility analysis in the UK (14), whereas the UK costs were recalculated in US dollars with an 
exchange rate of 1.8. Utilities were derived from US literature and are as follows (15): Baseline 
utility at the beginning of the study was 0.689. The disutility for (non-fatal) myocardial infarction 
was –0.052. The discount rate for both approaches was assumed to be 6%, which includes the 
expected inflation rate and the myopia of the population. The assumption that the discount rate 
is constant over time is due to the fact that the population’s myopia will not rapidly fluctuate and 
inflation is assumed to be relatively stable in the long term (16). As for the theoretical approach, 
only the costs are inflated and hence also discounted. The effects (quality-adjusted life-years, 
QALYs) are not discounted and also not inflated because the incremental effects for both 
approaches are assumed to be equal. 
The cumulative QALYs for treatment A after 10 years of treatment according to the 
assumed event rates (see table 1) are 65.02 for myocardial infarction. The cumulative QALYs for 
treatment B after 10 years of treatment are therefore 64.94.  
Table 1  Event rates for two hypothetical treatments: “Old” treatment A vs “new” treatment B  
Years 
Non-Cumulative number of myocardial 
infarction 1 2 3 4 5 6 7 8 9 10 
("Old") treatment B 2.6 3.8 4.4 5.5 7.3 7.2 8.5 11.5 11.1 14.2 
("New") treatment A 2.6 3.6 4.4 5.3 7.2 7.2 8.3 11.2 11.1 13.8 
 
Hypothetical case example to include constant yearly inflation rates 
The cost-effectiveness results are reported in table 2 (accepted cost-effectiveness 
approach without yearly inflation compared to results including inflation). The incremental cost-
effectiveness ratios (ICERs) were calculated after 10 years for the comparison of the “old” 
treatment B versus the “new” treatment A. Effects were the QALYs for the whole patient cohort, 
which was assumed to be 1,000 patients for each treatment arm at baseline. 
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Table 2  Comparison of cost-effectiveness approaches after 10 years of hypothetical treatment: Current approach (eq 1) 
vs “yearly inflation” approach with constant yearly inflation rates (eq 2) 
Myocardial infarction Costs Effects 
Incre-
mental 
costs 
Incre-
mental 
effects 
ICER 
 B A B A A-B A-B  
Current cost-effectiveness approach 
(without yearly inflation rates): Eq 1 
626,311 633,500 64.94 65.02 7,189 0.073 98,745 
Cost-effectiveness approach 
including yearly inflation rate: Eq 2 
735,578 739,167 64.94 65.02 3,590 0.073 49,309 
 
With the current approach the incremental cost-effectiveness ratio (ICERd, eq1) calculates a 
cost-effectiveness value of 98,745 US dollars for the event myocardial infarction (table 2). The 
high ICER (Incremental Cost Effectiveness Ratio) value was to be expected, due to the fact that 
the differences in the QALYs were marginal but the differences in the costs of complications 
were high. The inflation approach (ICERy, eq 2) results in a cost-effectiveness value of 49,309 
US dollars (table 2), which is within the cost-acceptability threshold of 55,000 US dollars (NICE 
threshold: approximately 25 - 35,000 pounds (17)). Note that the “new” treatment A is now more 
cost-effective in comparison to the “old” treatment B.  
Assuming a yearly inflation rate of 3% for health care expenditures (including 
pharmaceutical drugs) and a discount rate of 6%, the costs were underestimated by 17% after 
10 years when comparing the accepted cost-effectiveness approach with the approach we 
suggest (Table 3). The difference in cost-effectiveness increases proportionally, as per equation 
(eq 7). For myocardial infarction the cost differences between including and excluding yearly 
inflation result in 105,668 US dollars, or 17% of the overall costs incurred over 10 years. 
Therefore, the cost difference for the “new” treatment A is approximately 15% of the cumulative 
costs after 10 years. 
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Table 3  Cumulative costs of illness for the hypothetical treatments A (“new”) and B (“old”) treatments for the event 
myocardial infarction. Comparison between the current approach (eq 1) and the unadjusted discount approach with a 
constant yearly inflation rate (eq 2). Costs of illness are compared for the two approaches with and without the yearly 
inflation rate (eq 8).  
Myocardial 
infarction 
Year 
"Old" 
treatment  B 
without 
inflation (eq 
1) 
"New" 
treatment A 
without 
inflation (eq 1) 
"Old" treatment  
B including 
inflation (eq 2) 
"New" 
treatment  A 
including 
inflation (eq 2) 
Difference between 
"old" treatments with 
and without inflation 
(eq 8) 
Difference between 
"new" treatments with 
and without inflation 
(eq 8) 
1 22,444 22,483 22,463 32,058 19 9,575 
2 52,601 52,678 54,348 62,305 1,746 9,627 
3 89,450 89,564 92,368 100,357 2,918 10,793 
4 135,502 133,977 141,309 147,560 5,807 13,583 
5 195,775 194,285 208,202 213,579 12,427 19,294 
6 256,047 254,590 276,159 281,578 20,112 26,988 
7 325,521 324,097 358,785 362,304 33,264 38,207 
8 421,767 417,865 473,910 474,473 52,143 56,608 
9 514,666 510,794 588,367 588,976 73,701 78,181 
10 633,500 626,311 739,167 735,578 105,668 109,267 
 
Hypothetical case example to include varying yearly inflation rates 
The cost-effectiveness results for the approach including yearly varying inflation rates are 
shown in table 5. The assumptions for the analysis were the same as described above aside 
from the inflation rate variation in the first column of table 6. The costs could thereby be 
composed of pharmaceutical costs and their inflation rate (or even deflation rate, e.g. due to a 
reduction in costs in accordance with a particular health care policy), costs for the human 
resources (e.g. physician and nurses and their salary increases) and the costs for medical 
devices and their respective inflation rate. For this hypothetical analysis it is assumed that the 
weighted average of all cost increases is taken into account. This means that the different yearly 
variations in the inflation rate for the various categories, which are relevant for the treatment of a 
disease like myocardial infarction, are assumed to be known. For the base case analysis it is 
assumed that the varying inflation rates, for the above-mentioned categories, are the same for 
each category assuming the numbers of the CPI Medical Care services (9). 
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Table 4  Cost-effectiveness approaches in comparison after 10 years of hypothetical treatment: Current approach (eq 1) 
vs “yearly inflation” approach with varying yearly inflation rates (eq 2) 
Myocardial infarction Costs Effects 
Incre-
mental 
costs 
Incre-
mental 
effects 
ICER 
 B A B A A-B A-B  
Current cost-effectiveness approach 
(without yearly inflation rates): Eq 1 
626,311 633,500 64.94 65.02 7,189 0.073 98,745 
Cost-effectiveness approach 
including yearly inflation rates: Eq 2 
819,453 824,755 64.94 65.02 5,303 0.073 72,837 
 
The results of the current approach for the incremental cost-effectiveness ratios (ICER) are the 
same as in the above analysis. The inflation approach including varying inflation rates per year 
results in a cost-effectiveness value of 72,837 US dollars for myocardial infarction which is now 
higher than without the inclusion of a yearly varying inflation rate. When considering a cost-
acceptability threshold of 55,000 US dollars per QALY the new treatment A would likely not be 
accepted by health authorities. 
The cost differences between the current approach without including the yearly inflation rate and 
the yearly varying inflation rate approach add up to 191,255 US dollars, which is approximately 
30% of the total costs incurred during the time horizon of 10 years. The cost difference for the 
“new” treatment A is about 23% of the cumulative costs after 10 years (table 4). 
Table 5  Cumulative costs of illness for the hypothetical treatments A (“new”) and B (“old”) treatments for the event 
myocardial infarction. Comparison between the current approach (eq 1) and the yearly varying inflation approach (eq 2). 
Costs of illness are compared for the two approaches with and without the yearly inflation rate (eq 10). 
Myocardial 
infarction 
Year 
"Old" 
treatment  B 
without 
inflation (eq 
1) 
"New" 
treatment A 
without 
inflation (eq 1) 
"Old" treatment  
B including 
inflation (eq 2) 
"New" 
treatment  A 
including 
inflation (eq 2) 
Difference between 
"old" treatments with 
and without inflation 
(eq 10) 
Difference between 
"new" treatments with 
and without inflation 
(eq 10) 
1 22,444 22,483 22,913 32,470 469 9,986 
2 52,601 52,678 55,207 63,105 2,605 10,427 
3 89,450 89,564 93,100 101,028 3,649 11,465 
4 135,502 133,977 142,464 148,642 6,962 14,665 
5 195,775 194,285 210,548 215,840 14,773 21,555 
6 256,047 254,590 283,704 289,044 27,657 34,453 
7 325,521 324,097 377,059 380,253 51,538 56,156 
 Stefan Walzer – 5 Essays in Health Economics 25 
8 421,767 417,865 511,920 511,651 90,152 93,786 
9 514,666 510,794 641,976 641,763 127,310 130,969 
10 633,500 626,311 824,755 819,453 191,255 193,141 
 
For a more comprehensive analysis, the following inflation rates and weights for the costs were 
assumed: 
In this example, we assume that several cost centers influence the overall costs of the 
myocardial infarction treatment and hence the price range for this treatment changes over time. 
The weights for the various cost centers are hypothetical: 60% of the overall costs are 
dependent on centers other than human resources, pharmaceuticals and medical devices. The 
weights for medical devices and drugs are assumed to be 10%, respectively, and the weight for 
human resources (physicians, nurses) is assumed to be 20%. The inflation rates for the groups 
were derived from official figures from the US Department of Labor, Bureau of Labor Statistics 
(table 6). 
Table 6 Price changes for different cost centers related to the treatment of a myocardial infarction (9) 
Year OTHERS                               
(CPI Medical care 
services, USA) 
HUMAN RESOURCES                       
(Education and health 
services (AVERAGE WEEKLY 
EARNINGS, 1982 DOLLARS)) 
MEDICAL DEVICES                             
(Producer Price Index 
Industry Data 
(Pharmaceuticals and 
Medicines)) 
PHARMACEUTICALS                                 
(Producer Price Index Industry Data 
(Pharmaceutical preparations, acting 
on the cardiovascular system)) 
1995 5.06 -0.07 2.23 3.00 
1996 3.66 -0.06 1.40 4.50 
1997 2.88 1.98 1.99 4.12 
1998 3.22 2.14 9.90 5.53 
1999 3.36 0.83 3.45 1.46 
2000 4.27 0.57 2.67 0.83 
2001 4.81 2.50 2.23 3.22 
2002 5.06 2.74 2.63 3.95 
2003 4.47 0.39 4.02 3.93 
2004 5.00 1.03 3.74 4.81 
 
The results of the current approach for the incremental cost-effectiveness ratios (ICER) are the 
same as in the above analysis. The inflation approach including varying inflation rates for the 
various cost centers per year results in a cost-effectiveness value of 65,465 US dollars, which is 
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now higher than without the inclusion of a yearly varying inflation rate but still lower in 
comparison to the more stringent assumption of varying inflation rates for the overall costs (table 
7). At a cost-acceptability threshold of 55,000 US dollars per QALY, the new treatment A would 
again probably no longer be accepted. 
Table 7 Cost-effectiveness approaches in comparison after 10 years of hypothetical treatment: Current approach (eq 1) 
vs “yearly inflation” approach with varying yearly inflation rates (eq 2) assuming varying price changes for various cost 
centers 
 
Myocardial infarction Costs Effects 
Incre-
mental 
costs 
Incre-
mental 
effects 
ICER 
 B A B A A-B A-B  
Current cost-effectiveness approach 
(without yearly inflation rates): Eq 1 
626,311 633,500 64.94 65.02 7,189 0.073 98,745 
Cost-effectiveness approach 
including yearly inflation rates: Eq 2 
773,782 778,548 64.94 65.02 4,766 0.073 65,465 
 
The cost differences between the accepted approach without including the yearly inflation rate 
and the approach we suggest (including yearly varying inflation rates) add up to 145,048 US 
dollars, or 23% of the total costs incurred over a 10 year time horizon (table 8). The cost 
difference for the “new” treatment A is 19% of the cumulative costs after 10 years (table 4). 
Table 8 Cumulative costs of illness for the hypothetical treatments A (“new”) and B (“old”) treatments for the event 
myocardial infarction. Comparison between the current approach (eq 1) and the yearly varying inflation approach (eq 2). 
Costs of illness are compared for the two approaches with and without the yearly inflation rate (eq 10) assuming varying 
price changes for various cost centers 
Myo-cardial 
infarction 
Year 
"Old" 
treatment  B 
without 
inflation (eq 
1) 
"New" 
treatment A 
without 
inflation (eq 1) 
"Old" treatment  
B including 
inflation (eq 2) 
"New" 
treatment  A 
including 
inflation (eq 2) 
Difference between 
"old" treatments with 
and without inflation 
(eq 10) 
Difference between 
"new" treatments with 
and without inflation 
(eq 10) 
1 22,444 22,483 22,582 31,917 138 9,434 
2 52,601 52,678 54,326 62,031 1,725 9,353 
3 89,450 89,564 92,056 99,793 2,606 10,229 
4 135,502 133,977 142,735 148,671 7,233 14,694 
5 195,775 194,285 208,581 213,658 12,806 19,373 
6 256,047 254,590 276,650 281,771 20,603 27,180 
7 325,521 324,097 364,652 367,749 39,131 43,651 
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8 421,767 417,865 491,346 491,186 69,579 73,321 
9 514,666 510,794 611,477 611,366 96,811 100,571 
10 633,500 626,311 778,548 773,782 145,048 147,471 
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Discussion 
Yearly inflation rates can be observed in the health care market of all industrialized countries. 
Even in countries with a national health care system, as in the United Kingdom or Italy, health 
care costs increase every year. The analysis presented herein shows that the results of cost-
effectiveness analyses may be biased when varying inflation rates are not considered. 
Current guidelines for the evaluation of new pharmaceutical products do not take yearly varying 
inflation rates into account. Furthermore the guidelines only consider the adjusted discount 
rates, which means that the results are already biased, equations (eq 7) and (eq 9). 
Lipscomb et al. (10) recommend adjusting the discount rate with the inflation rate in a chapter of 
the current gold-standard guideline about cost-effectiveness analysis – Gold et al. But also this 
recommendation could be biased as the analysis above shows. That biases might also appear in 
the results related to the current cost-effectiveness approach when comparing them to an 
approach including a yearly inflation rate. 
On the other hand, the guide published by the Panel on Cost-effectiveness in Health and 
Medicine (18) has recognised the problem of future costs directly related to the disease in 
question. The authors note the importance of considering increasing costs over time and they 
admit to methodological problems e.g. by modelling the medical CPI. Since it is difficult to 
forecast the inflation rate, future research should aim to analyse the possible bias when 
estimating future inflation rates on the basis of prior precedent. Nonetheless, it is essential to 
seperate the inflation rate into the part related to higher productivity, e.g. caused by innovations, 
and the part directly related to the increase of costs. Luce et al. (18) recommend using the yearly 
inflation rate approach to analyse the correct influence of costs, especially for cost-effectiveness 
analyses, which are done for chronic diseases with a long time horizon. The above analysis 
supports the recommendation by the cost-effectiveness panel. It is essential to take the yearly 
inflation rate into account to prevent the health authorities from using biased cost-effectiveness 
ratios. 
 
Current guidelines published by health authorities throughout the world (1-7,13) do not explicitly 
advise health economists on the problem of future health care costs and the related inflation 
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rate. The NICE guideline (1), for instance, speaks about a sufficient time horizon to reflect the 
impact on costs and effectiveness, especially for chronic diseases. They also mention the 
importance of using a discount rate to calculate future costs for the present. Due to the varying 
inflation rates in the course of time, it would also be important to compare cost-effectiveness 
analyses for health technology assessments when the yearly inflation rate is included. 
 
In the light of the recommendations by the Washington panel on cost-effectiveness analyses as 
well as the hypothetical and theoretical results of this study, it is advisable to include the yearly 
inflation rates for long-term analyses in the economic evaluation separately from the discount 
rate. Additional estimations for the yearly varying inflation rates should also be taken into 
account. Further research on real effectiveness and cost data is recommended. 
 
The new investigated method with the inclusion of variable unadjusted discount rates and 
inflation rates should be used for long-term analysis in Health Economics. The presentation of 
the results will allow decision makers to get an impression of the influences of the above 
mentioned uncertainty and how maybe a result based on the old method would lead to a false 
negative or false positive conclusion in terms of cost-effectiveness or reimbursement. 
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Appendix 
 
Appendix 1: Derivation of the Taylor series for the comparison between the current cost-effectiveness approach and a 
yearly but constant inflation rate approach 
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When using the Taylor series the following expression can then be computed: 
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Appendix 2: Derivation of the Taylor series for the comparison between the current cost-effectiveness approach and a 
yearly, varying inflation rate approach 
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When using the Taylor series the following expression can then be computed: 
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Abstract 
Background: Nearly 5 million children in the United States are affected by asthma, which is 
more than 5 percent of the population younger than 18 years. In children four years or younger, 
the prevalence increased 160 percent from 1980 to 1994. There are several effective drugs that 
relieve the symptoms of asthma and others are currently being developed but even when these 
medications are prescribed, they may be underutilized because parents fear the possibility of 
adverse events. Up to now there is no knowledge which are the main drivers of caregiver’s 
preferences for a safe and effective medication for pre-school children in general. The study 
population were caregivers with children aged 4 years or below. Sample size was 42, results 
were checked by Monte-Carlo simulation. 
Material and Methods: For a conjoint analysis a status quo treatment and hypothetical 
treatment options were defined by four attributes: Episode free days, risk of exacerbation, 
information available for the long-term impact of the treatment and out-of-pocket expenses. It 
was possible to use the status quo as the reference scenario, permitting to couch this ranking in 
terms of a decision to purchase the product. Relative importance for each product attribute as 
well as utility estimations for each attribute level were calculated.  
Results and Discussion: The overall result was that the most important feature for an asthma 
treatment, in this study, was the attribute episode free days. On a scale from 0 to 100 this 
attribute got the calculated relative importance of 44.2. In contrast to this finding is the relative 
importance of the attribute EXACERBATION, which only reached 16.2, which is the most 
unimportant attribute of the attributes offered. Even the variable INFORMATION available on 
long-term effects in children between 4 years and 14 years of age was more important than the 
side effects (19.2). Out-of-pocket expenses per month were the second most (relative) important 
attribute (20.5). 
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Introduction 
Asthma is a chronic disease that effects between 9 and 12 million persons in the United States 
[1] and is the most common chronic disease of childhood [2]. Nearly 5 million children in the 
United States are affected by asthma, which is more than 5 percent of the population younger 
than 18 years [3]. It is the leading cause of lost school days in children [4, 5]. In children four years 
or younger, the prevalence increased 160 percent from 1980 to 1994. To avoid the missing 
school days pre-school children should be treated in the most effective way as possible. There 
are several effective drugs that relieve the symptoms of asthma and others are currently being 
developed but even when these medications are prescribed, they may be underutilized because 
parents fear the possibility of adverse events and long-term effects. Up to now there is no 
knowledge which are the main drivers of caregiver’s preferences for a safe and effective 
medication for pre-school children in general. 
Asthma or wheezing conditions was not explicitly defined. Respondents were screened based 
on the asthma medication that the child is currently taking for the treatment of the condition. 
Severity of asthma / wheezing condition was identified by applying the "Evaluation of a short 
form for measuring health-related quality of life among pediatric asthma patients". 
For an economic evaluation (such as a preference study) of treatments in diseases such as 
asthma, where a substantial impact is on quality of life rather than survival, it is crucial to be able 
to incorporate the effects of the new therapies on quality of life and include those effects in the 
economic evaluation. Within health care there is substantial evidence to suggest that, in addition 
to the treatment outcome (that is, the effectiveness), other aspects of the process of receiving 
treatment are also important for individuals [6, 7, 8, 9]. Conjoint analysis was originally developed for 
market research into consumer preferences, and is a method that investigates the relative 
importance of groups of attributes, e.g., products with certain properties or more abstract 
concepts such as treatment procedures [10, 11]. It has been applied to various aspects of health 
care; for reviews, see Ryan 1996 [12] or Szeinbach et al. 1999 [13]. The method can thus be used 
to analyze patient preferences for various treatment alternatives. 
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No asthma treatment regimen is likely to have all the attributes that patients would ideally like; 
for example, a regimen might be highly effective (desirable) but expensive (undesirable). 
Conjoint analysis provides a method of “trading off” desirable attributes against undesirable 
ones, and assessing which attributes are most important in determining the patient preferences 
for one regimen over another. The target population of this study is pre-school children with a 
maximum age of 4 years. Obviously the possibility to ask the children themselves was naturally 
limited and hence the caregivers answered for them.  
The purpose of this study was to evaluate, using conjoint analysis, asthma patients’ preferences 
for different aspects of asthma treatment, including efficacy (episode free days), side effects (risk 
of exacerbation), available information by the FDA about long-term effects, and out-of-pocket 
expenses. The relative importance was evaluated for each of the described attributes. 
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Materials and Methods 
The methods used for the discrete choice part of this study were already explained in a recent 
paper (14). The study protocol was conducted in accordance with the Declaration of Helsinki and 
approved by local ethics committees, and all participants gave written informed consent. 
 
It is assumed that the preferences of caregivers of pre-school children with asthma could be 
taken as approximations for the utility of their child for a given treatment. If the caregiver is a 
pure altruist with respect to the child, i.e. cares but respects the child’s preferences, the 
caretaker’s responses will reflect the child’s preferences. For the present analysis caregivers 
were asked to choose between two hypothetical asthma treatments for their child. The decision 
was based on a status quo treatment versus a new (hypothetical) treatment with changed 
attribute levels. Possible attributes and their levels were tested in various face-to-face interviews 
with caregivers in autumn 2005. Potential and actual study participants were contacted based on 
information from a consumer database in the United States. The tested attributes were ease of 
handling, efficacy (episode free days), time for administration, number of administrations per 
day, side effects (risk of asthmatic exacerbation), available information by the FDA (information 
on long-term effects in children between 4 and 14 years of age) as well as expenses. This pre-
test was deducted mainly as qualitative interviews with seven applicants (see table 1). It turned 
out that the main attributes for the treatment of asthma were expenses, episode free days, side 
effects and available information by the FDA.  
Table 1: Product attributes and levels retained in the main survey 
Attributes Label Levels Value labels 
Episode free days 
FREEDAYS Increase from 180 to 200 episode free days 
per year 
200 
  Increase from 180 to 220 episode free days 
per year 
220 
  Decrease from 180 to 1600 episode free days 
per year 
180 
  Decrease from 180 to 140 episode free days 
per year 
140 
Exacerbation EXACERBATION Risk of EXACERBATION: 6% of patients 
develop a mild to severe EXACERBATION 
6 
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  Risk of EXACERBATION: 10% of patients 
develop a mild to severe EXACERBATION 
10 
  Risk of EXACERBATION: 16% of patients 
develop a mild to severe EXACERBATION 
16 
Information about long-
term effects by the FDA 
available 
INFORMATION INFORMATION available on long-term effects 
in children between 4 years and 14 years of 
age 
1 
  No INFORMATION available on long-term 
effects in children between 4 years and 14 
years of age 
2 
Out-of-pocket 
EXPENSES 
EXPENSES $10 per month 10 
  $30 per month 30 
  $50 per month 50 
 
Pre-test interviews resulted in the fact that the main attributes for the treatment of asthma were 
expenses, episode free days, side effects and available information by the FDA (14).  
In conjoint analysis, several attributes of treatment are selected and a range of possible values 
(“levels”) are defined for each attribute. These are used to create a number of treatment 
concepts, each with different levels for the various attributes. The levels of attributes were 
defined as follows (see table 1): ‘Episode free days’ (FREEDAYS), symbolizing the change in 
the risk to develop asthma attacks from an unknown individual level, takes on changes from 180 
days (baseline [15]) to 200 and 220 days per year as well as a possible decrease in change to 
160 and 140 days per year. ‘Exacerbation’ (EXACERBATION), defined as developing mild or 
moderate exacerbation, varies between levels of 6%, 10% and 16%. A recent study with adults 
has shown that mild to moderate asthmatic patients are very much affected by their disease and 
patient’s utility was decreasing when developing an exacerbation [16]. It is assumed that these 
findings are also valid in pre-school children. For the FDA ‘information’ on long-term effects 
(INFORMATION) in children between 4 and 14 years of age two levels were used: Availability or 
non availability. Other studies have shown that caregivers could be concerned about the missing 
long-term effects of asthma treatment in pre-school children [17]. The ‘out-of-pocket cost’ 
(EXPENSES) per month ranges from $10, $30 to $50. Status quo treatment (see table 2) was 
defined as having 180 episode free days per year and a risk to develop a mild or severe 
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exacerbation of 10%. Information by the FDA is available and the monthly out-of-pocket 
expenses are $20. 
Table 2: Status quo treatment – definition by attribute levels 
Attributes Levels 
Episode free days 180 episode free days per year 
EXACERBATION Risk of EXACERBATION: 10% of patients 
develop a mild to severe EXACERBATION 
INFORMATION availability INFORMATION available on long-term effects 
in children between 4 years and 14 years of 
age 
Out-of-pocket EXPENSES $20 per month 
 
Since the second and the last attributes have 3 levels each, while FREEDAYS has 4 and 
INFORMATION has two, the number of scenarios amounts to a total of 72 (= 4*3*2*3). 
Techniques have been developed to reduce the number of possible scenarios while still being 
able to infer utilities for all combinations of levels of the attributes [18]. Using the ORTHOPLAN 
procedure, which implicitly assumes a linear utility function, programmed in the software 
package SPSS, the design was reduced to 16 scenarios. All study participants had to answer 
these 16 variants as well as two hold-out cards whereas the scenarios were randomly assigned 
to take care of a possible question ordering bias [19]. With regard to each variant, respondents 
had to indicate whether or not they would choose the treatment and would pay the monthly out-
of-pocket expenses (for a sample card presented to study participants, see Appendix A.1). 
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Results 
Descriptive statistics 
In table 3, descriptive statistics of the caregivers with regard to the dependent and explanatory 
variables are reported. Nearly all caregivers who took part in the survey were female (92.9%). 
The average of the respondents have one child. Caregivers were also asked how confident they 
are in knowing what they do when they are thinking about their overall ability to take care of their 
family’s general health – eating right, getting check-ups, taking medicine, deciding when to see 
the doctor. Within the whole population 42.9% agreed with the statement feeling “Very confident” 
and another 26.7% agreed with the statement feeling ”Extremely confident”. Summarized 31% 
felt fairly and/or somewhat confident and 69% of caregivers felt very and/or extremely confident.  
In 18% of the cases the doctor never told the caregiver the asthma severity diagnosis of their 
child. Anyway, 21.4% of caregivers rated the severity of their child as very mild, whereas no 
physician diagnosed a child with that rate. Also differences in diagnosing severe asthma could 
be detected: 4.8% of physicians diagnosed children as having severe asthma whereas only 
2.4% of caregivers diagnosed so.  
Table 3: Descriptive Statistics of caregivers 
 Percent 
Cumulative 
Percentage 
Gender 
Female 92.9  
Age 
<30 years 28.6  
30 – 39 years 42.8 71.4 
40 – 49 years 19.1 90.5 
>50 years 9.5 100 
Number of children < 4 years 
1 child 73.8  
2 children 26.2 100 
Rating of health care 
Fairly/somewhat confident 31.0  
Very/extremely confident 69.0 100 
Number of children with diagnosed asthma and/or wheezing conditions 
1 child 73.8  
2 children 26.2 100 
Relationship to children 
Mother or female guardian 85.7  
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Father or male guardian 7.1 92.9 
Grandparent 7.1 100 
Level of education 
High school graduate (or lower) 11.9  
Some college 31.0 42.9 
Associate / Bachelor’s degree 40.5 83.3 
Postgraduate school 14.3 97.6* 
Current employment situation 
Working full-time 40.5  
Working part-time 11.9 52.4 
Homemaker 45.2 97.6** 
Annual household income in 2004 
< US$25,000 4.8  
US$ 25,000 – 49,999 45.2 50.0 
US$ 50,000 – 74,999 19.0 69.0 
> US$ 75,000 23.8 92.9*** 
Smoking 
Smoker 28.6  
Non-Smoker 71.4  
Severity estimation by caregiver 
Very mild 21.4  
Mild 35.7 57.1 
Moderate 40.5 97.6 
Severe 2.4 100 
Severity diagnosis by physician 
Mild 35.7  
Moderate 40.5 76.2 
Severe 4.8 81.0 
Doctor never told me the severity 19.9 100 
Compliance estimation for other caregivers 
< 20% 54.8  
20% - 39% 23.8 78.6 
40% - 59% 7.1 85.7 
> 60% 14.3 100 
Own compliance estimation 
< 10% 76.2  
10% - 19% 11.9 88.1 
20% - 29% 4.8 92.9 
> 30% 7.1 100 
Children characteristics Percent Cumulative Percent 
Age 
< 2 years (child 1) 33.3  
< 2 years (child 2) 0  
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Gender 
Female (child 1) 35.7  
Female (child 2) 66.7  
Race 
White 88.1  
Black 4.8 92.9 
Other 7.1 100 
Medications currently taken (more than one drug could be chosen) 
Accolate 2.4  
Advair 2.4  
Flovent 7.1  
Pulmicort Respules 28.6  
Singulair 76.2  
Prevalence of asthma 88.1  
Prevalence of wheezing conditions 26.2  
Prevalence of allergies 71.4 -- 
Cough in last 4 weeks 
Never 14.3  
A few days 31.0 45.3 
Some days 23.8 69.1 
Most days 19.0 88.1 
Every day 11.9 100 
Wheezing conditions in last 4 weeks 
Never 26.2  
A few days 33.3 59.5 
Some days 35.7 95.1 
Every day 2.4 97.6**** 
Shortness of breath in last 4 weeks 
Never 57.1  
A few days 16.7 73.8 
Some days 19.0 92.8 
Most of the days 4.8 97.6**** 
Asthma attacks in last 4 weeks 
Never 85.7  
A few days 9.5 95.2 
Some days 2.4 97.6 
Most of the days 2.4 100 
Number of asthma attacks in last 4 weeks 
0 16.7  
1 attack 50.0 66.7 
2 attacks 16.7 83.3 
6 attacks 16.7 100 
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Awakened in last 4 weeks due to asthma/wheezing conditions 
Never 38.1  
A few days 40.5 78.6 
Some days 16.7 95.2 
Most of the days 4.8 100 
* Other education: 2.4%; ** Retired: 2.4%; *** Declined to answer: 7.1%;  
**** Don’ know: 2.4% 
 
Caregivers were also asked about their estimation of how many caregivers (in general) forget to 
provide the asthma medication for their child during a week due to several reasons (job stress, 
care for other children, etc.) in one week on average. In various studies it turned out that up to 
95% of caregivers (on average around 50%) don’t give the medication in the right way (not 
regularly, wrong dosage, etc.) [26, 27]. Study respondents estimated that 16.7% of other caregivers 
never forget this per week. 54.8% estimated that a maximum of 19% forget the medication of 
their child. But when asking in how many cases the caregivers itself forget it 88.1% say that they 
forget this themselves at a maximum of 19%. When estimating for other caregivers the 
cumulative 88% is reached for around 69% of caregivers who will forget offering the (correct) 
treatment, which is nearly the number that could be found in the literature. 
The medications children currently taking for the treatment of asthma and/or wheezing 
conditions are distributed in this sample as follows, whereas more than one drug could be taken 
for treatment: 76.2% are taking Singulair, 28.6% Pulmicort Respules, 7.1% Flovent and Accolate 
and Advair are taken each by 2.4. During the last 4 weeks in advance of the survey 23.8% of 
children have had experienced cough on some days whereas 19% experienced this 
complication most days. 11.9% of children experienced cough every day. The condition 
wheezing was less often experienced every day (2.4%) but nearly 33% have experienced 
wheezing a few days in the last 4 weeks. Caregivers reported that 57.1% of their children never 
had shortness of breath but also 19% reported that their children experienced that symptom 
some days in the last month. Asthma attacks in this study population were not that frequent 
(never experienced in the last 4 weeks: 85.7%) with experiences of this symptom a few days in 
9.5%. Anyway of those who experienced asthma attacks 50% had one attack in the last month, 
16.7% had two and another 16.7% had six asthma attacks. The possibility of awaken during the 
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night due to asthma/wheezing conditions, such as asthma attacks, etc., was relatively frequent 
but not that severe: 38.1% never awakened, 40.5% awakened a few nights, 16.7% some nights 
but also 4.8% awakened each night. 
52.4% of pediatricians of these children offered most or all the time treatment choices to the 
caregivers (table 4). While they were doing so, the physicians also discussed the pros and cons 
of the offered/suggested treatments. After discussions with caregivers, they stated that 
pediatricians take their preferences into account when making treatment decisions for their 
child’s asthma or wheezing conditions care. This could be taken as an indication that these 
caregivers should be interested in available information by the FDA on long-term effects. 
Additionally 85.7% of caregivers reported to follow the asthma or wheezing conditions 
medication schedule given to them by their child’s doctor or nurse. On the other hand around 
90% mentioned that they provide medications to their child when they feel it was appropriate. 
Table 4: Treatment behavior of caregivers 
 Percent Cumulative Percent 
Physician offers treatment choices in child's asthma or wheezing conditions care 
All of the time 28.6  
Most of the time 23.8 52.4 
Some of the time 28.6 81.0 
A little of the time 2.4 83.3 
None of the time 16.7 100 
Physician discusses the pros and cons of each treatment choice with you 
All of the time 35.7  
Most of the time 33.3 69.0 
Some of the time 9.5 78.6 
A little of the time 7.1 85.7 
None of the time 14.3 100 
Physician takes your preferences into account when making treatment decisions for your 
child 
All of the time 35.7  
Most of the time 40.5 76.2 
Some of the time 9.5 85.7 
A little of the time 4.8 90.5 
None of the time 9.5 100 
I follow the asthma or wheezing conditions medication schedule given to me by my child's 
doctor or nurse 
Yes 85.7  
No 14.3 100 
I provide asthma or wheezing conditions medication(s) to my child when I feel is appropriate 
Yes 90.5  
No 9.5 100 
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Conjoint analysis 
Results from the discrete choice decisions served as a basis for a conjoint analysis [11]. Relative 
importance for each product attribute as well as utility estimations for each attribute level were 
calculated.  
For the caregivers the key attribute for an asthma drug for the treatment of childhood asthma is 
FREEDAYS. On a scale from 0 to 100 this attribute got the calculated relative importance of 
44.2 (see figure 1).  
Figure 1: Relative importance of Factors for Treatment of Pediatric Asthma and/or Wheezing Conditions. Base Case based 
on the real number of respondents in comparison to 100 iterations from a Monte-Carlo simulation 
 Base Case 100 iterations 
FREEDAYS 44.189 40.303 
EXACERBATION 16.181 16.667 
INFORMATION 19.153 17.362 
EXPENSES 20.477 25.668 
 
In contrast to this finding is the relative importance of the attribute EXACERBATION, which only 
reached 16.2, which is the most unimportant attribute of the attributes offered. Even the variable 
INFORMATION available on long-term effects in children between 4 years and 14 years of age 
was more important than the side effects (19.2). Out-of-pocket expenses per month were the 
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second most (relative) important attribute, whereas it was only slightly more important than the 
attribute INFORMATION (20.5). 
The utilities for the efficacy attribute (FREEDAYS) are positive for the increase of episode free 
days and negative for the decrease of episode free days (see table 5). However, the utility is not 
increasing with the increasing number of episode free days. Anyway with decreasing episode 
free days the utilities are also decreasing. The utilities for the increasing out-of-pocket 
EXPENSES were decreasing with the growing costs. Furthermore the utility for the available 
information is positive and vice versa.  
Table 5: Conjoint analysis – Utility estimations (Base Case) 
  Utility Estimate Std. Error 
FREEDAYS 
Increase episode free days 180 to 200 .057 .038 
Increase episode free days 180 to 220 .039 .038 
Decrease episode free days 180 to 160 -.045 .038 
Decrease episode free days 180 to 140 -.051 .038 
EXACERBATION 
6% develop an EXACERBATION .036 .027 
10% develop an EXACERBATION .071 .053 
16% develop an EXACERBATION .107 .080 
INFORMATION 
INFORMATION available -.060 .044 
No INFORMATION available -.119 .088 
EXPENSES 
$10 -.018 .027 
$30 -.037 .053 
$50 -.055 .080 
(Constant) .116 .096 
 
The conjoint analysis’ findings were also tested for its possibilities to predict the observed 
values: Pearson’s R was relatively good (0.73) as well as Kendall’s tau (0.54), whereas both 
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measures were highly significant for the correlation between the observed and predicted values 
(see table 6). Furthermore Kendall’s tau for the hold-out cards is 1. 
Table 6: Conjoint analysis - Correlations between observed and estimated preferences 
  Value Sig. 
Pearson's R .703 .001 
Kendall's tau .543 .002 
Kendall's tau for Holdouts 1.000 . 
 
Sensitivity Analysis 
Due to budget restrictions, only 42 respondents could be included in this survey. However, to 
improve the validity and significance of the study the data have also been simulated by 100 
Monte-Carlo iterations. Monte-Carlo simulations are reproducing data dependent on the input 
data and their corresponding distributions. In this way it can be checked how sensitive the 
underlying base data are to changes in the inputs. For the simulation the binomial distribution 
was assumed for the simulation of the outcome “Scenario”. For the caregiver’s socio-economic 
characteristics a beta-pert distribution was assumed to stay within the calculated ranges of the 
parameters given by the study participants [20]. It turned out that the ranking for the relative 
importance of the four attributes is not changed when using 100 iterations (see figure 1), which 
was used as having 100 respondents. This procedure is state-of-the-art for checking uncertainty 
around the data in economic evaluation studies [20]. 
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Discussion 
This study has investigated patient preferences for different attributes of asthma treatment in 
pre-school children. The overall result was that the most important feature for an asthma 
treatment in this study was the episode free days.  
The major criticism about the study is the small sample size of 42 respondents. Due to this fact 
the results could be biased due to outliers who could be overweighed. Within a larger population 
the results could maybe more smoothed and outliers would not be overweighed as can be 
assumed in a small sample size. However in a Monte-Carlo simulation study, which was done 
along that original study using the study data, it turned out that the conjoint results are relatively 
stable and could give a first impression about preferences for a treatment within such a special 
population like caregivers of asthmatic children. 
The attribute EXACERBATION turned out to be the most unimportant attribute in the base 
analysis also when comparing with the variable INFORMATION available on long-term effects in 
children between 4 years and 14 years of age. This finding could maybe be explained that 
caregivers weight the possible long-term effects, which should be explained by the FDA 
information, higher than the short-term side effects like the risk of an asthmatic exacerbation. 
The utilities for each attribute level was in the range as expected with two exceptions: The utility 
for the efficacy attribute is not increasing with the increasing number of episode free days. One 
possible explanation for this could be that the caregivers did not believe that the efficacy would 
increase by nearly 22% (possible theoretical misspecification bias [19]) - from 180 days to 220 
days. Anyway with decreasing episode free days the utilities are also decreasing. 
Counterintuitive is the finding for the utilities of the risk of exacerbations: The higher the 
probability of an exacerbation, the higher the utility. Maybe the relative low importance of that 
attribute could lead to that finding, i.e. that the other positive impacts traded the negative impact 
of this attribute out. Additionally only few children experienced (very) often shortness of breath or 
much asthma attacks in the last four weeks in advance of the study. Maybe caregivers are less 
risk averse on this attribute when comparing it to the other three. Of course this could be a major 
caveat of the study, however the aim of a discrete choice analysis is to have respondents 
switching between the status quo and the offered (hypothetical) products to calculate the relative 
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importance for the various attributes [13]. Additionally the finding for the utilities of the risk of 
exacerbations was also counterintuitive: The higher the probability of an exacerbation, the higher 
the utility. One explanation for this could be the characteristics of discrete choice analysis, i.e. 
that the (positive) impacts of the other attributes traded the negative impact of this attribute out. 
Additionally only few children experienced (very) often shortness of breath or much asthma 
attacks in the last four weeks in advance of the study. Maybe caregivers are less risk averse on 
this attribute when comparing it to the other three. 
In this application the discrete-choice conjoint analysis requires respondents only to indicate 
whether they prefer one scenario over another. Moreover, it was possible to use the status quo 
as the reference scenario, permitting to couch this ranking in terms of a decision to purchase the 
product. The conjoint method has been used for decades in other research disciplines, notably 
consumer market research, but has only recently started to be used to study asthma. Osman et 
al [27] used conjoint analysis to rank asthma symptoms. Another study [29] investigated 
preferences for a limited number of aspects (need for blood test monitoring, frequency of dosing, 
and route of administration) for asthma controller medication. To our best knowledge this study 
is the first one, which analyzed the impact of various treatment attributes on the relative 
importance of caregivers for their pre-school children’s asthma treatment. Obviously the sample 
size is relatively small due to budget restrictions, anyway the results should be important in the 
ranking of attribute’s importance in pre-school children in chronic diseases. Furthermore the 
children who participated in the present study are not representative and thus the generalisability 
of the results is uncertain; e.g. the children were typically first-born children with very mild 
asthma and working mothers with university degrees. Hence the following findings have to be 
interpreted always in the background of the cohort characteristics. The findings of this study 
based on the aggregated results from 42 caregivers with children having asthma and/or 
wheezing condition can be summarized as follows. Caregivers focused primarily on the 
effectiveness of a treatment (episode free days). Ranking in terms of importance of expenses, 
availability of long-term effects and risk of exacerbation is strongly dependent on the risk 
aversion of the caregiver.  
 Stefan Walzer – 5 Essays in Health Economics 51 
References 
(1) Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in 
the United States. N Engl J Med. 1992 Mar 26; 326 (13): 862-6 
(2) Centers for Disease Control and Prevention (CDC). Measuring childhood 
asthma prevalence before and after the 1997 redesign of the National 
Health Interview Survey-United States. MMWR Morb Mortal Wkly Rep. 
2000 Oct 13; 49 (40): 908-11 
(3) Adams PF, Marano MA. Current estimates from the National Health 
Interview Survey, 1994. Vital Health Stat 10. 1995 Dec; (193 Pt 1): 1-260 
(4) National Hospital Discharge Survey: annual summary, 1993. Vital Health 
Stat 13. 1995 Aug; (121): 1-63 
(5) Taylor WR, Newacheck PW. Impact of childhood asthma on health. 
Pediatrics. 1992 Nov; 90 (5): 657-62 
(6) Ratcliffe J, Buxton M. Patients' preferences regarding the process and 
outcomes of life-saving technology. An application of conjoint analysis to 
liver transplantation. Int J Technol Assess Health Care. 1999 Spring; 15 (2): 
340-51 
(7) Using conjoint analysis to assess women's preferences for miscarriage 
management. Health Econ. 1997 May-Jun; 6 (3): 261-73 
(8) Ryan M. Using conjoint analysis to take account of patient’s preferences 
and go beyond health outcomes. An application to in-vitro fertilisation. Soc 
Sci Med 1999; 48: 535–46 
(9) Johansson G, Ställberg B, Tornling G et al. Asthma treatment preference 
study: A conjoint analysis of preferred drug treatments. Chest. 2004 Mar; 
125(3): 916-23 
(10) Srinivasan V, Shocker AD. Linear programming techniques for 
multidimensional analysis of preferences. Psychometrika 1973; 38 (3): 337–
69 
 Stefan Walzer – 5 Essays in Health Economics 52 
(11) Green PE, and Rao V. Conjoint measurement for quantifying judgmental 
data. Marketing Res 1971; 8: 355–63 
(12) Ryan M. Using consumer preferences in health care decision making: the 
application of conjoint analysis; Office of Health Economics. Luton, 
Bedfordshire, UK: White Crescent Press, 1996 
(13) Szeinbach SL, Barnes JH, McGhan WF et al. Using conjoint analysis to 
evaluate health state preferences. Drug Inf J 1999; 33:849–58 
(14) Walzer S, Zweifel P. Willingness-to-pay and risk aversion for caregivers of 
children with asthma or wheezing conditions. Working paper 2006 
(15) Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and 
budesonide on exacerbations of asthma. Formoterol and Corticosteroids 
Establishing Therapy (FACET) International StudyGroup. N Engl J Med. 1997 
Nov 13; 37 (20):1405-11 
(16) Andersson F, Borg S, Stahl E. The impact of exacerbations on the 
asthmatic patient's preference scores. J Asthma. 2003 Sep; 40 (6): 615-23 
(17) de Jongste JC, Janssens HM, Van der Wouden J. Effectiveness of 
pharmacotherapy in asthmatic preschool children. Allergy. 2002; 57 Suppl 
74: 42-7 
(18) Louviere, JJ, Hensher DA, Swait JD. Stated Choice Methods – Analysis and 
Application. Cambridge: Cambridge University Press, 2000 
(19) Mitchell RC, Carson RT. Using Surveys to Value Public Goods, The 
Contingent Valuation Method.: Washington, DC: Resources for the Future, 
1989 
(20) Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. 
Methods for the Economic Evaluation of Health Care Programmes. Oxford, 
New York. Oxford University Press 2005 
(21) Vose D. Risk analysis: A quantitative guide. 2nd ed. Chichester, New York, 
Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons, 2001 
 Stefan Walzer – 5 Essays in Health Economics 53 
(22) Zweifel P, Breyer F. Health Economics. New York, Oxford: Oxford 
University Press, 1997 
(23) Ben-Akiva M, Lerman SR. Discrete Choice Analysis. Cambridge, London: 
MIT Press, 1985 
(24) Janse AJ, Gemke RJ, Uiterwaal CSPM et al. Quality of Life: Patients and 
doctor’s don’t always agree: a meta-analysis. J Clin Epidemiol. 2004 
Jul;57(7): 653-61 
(25) Janse AJ, Gemke RJ, Uiterwaal CSPM et al. A difference in perception of 
quality of life in chronically ill children was found between parents and 
pediatricians. J Clin Epidemiol. 2005; 58 (5): 495-502 
(26) Moy ML, Fuhlbrigge AL, Blumenschein K et al. Association between 
preference-based health-related quality of life and asthma severity. Ann 
Allergy Asthma Immunol. Mar; 92(3): 329-34 
(27) Gibson NA, Ferguson AE, Aitchison TC. Compliance with inhaled asthma 
medication in preschool children. Thorax. 1995 Dec; 50 (12):1274-9 
(28) Reinhardt D, editor. Asthma bronchiale im Kindesalter. Berlin, Heidelberg, 
New York: Springer Verlag, 1999 
(29) Osman LM, McKenzie L, Cairns J, et al. Patient weighting of importance of 
asthma symptoms. Thorax 2001 Feb; 56 (2): 138-42  
(30) Balsbaugh TA, Chambers CV, Diamond JJ. Asthma controller medications: 
what do patients want? J Asthma 1999 Oct;36(7):591-6 
 Stefan Walzer – 5 Essays in Health Economics 54 
Appendix 
 
Appendix A.1: Example of a card presented to respondents 
 AGENT A AGENT B 
Episode free days 180 episode free days per 
year 
220 episode free days per year 
Exacerbation Risk of exacerbation: 10% of 
patients develop a mild to 
severe exacerbation 
 
Risk of exacerbation: 16% of 
patients develop a mild to 
severe exacerbation 
 
Information availability Information available on 
long-term effects in children 
between 4 years and 14 
years of age 
 
Information available on long-
term effects in children 
between 4 years and 14 years 
of age 
 
Out-of-pocket expenses $20 
 
$50 
 
   
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Abstract 
Background: Nearly 5 million children in the United States are affected by asthma, 
which is more than 5 percent of the population younger than 18 years. In children 
four years or younger, the prevalence increased 160 percent from 1980 to 1994. 
There are several effective drugs that relieve the symptoms of asthma and others are 
currently being developed but even when these medications are prescribed, they 
may be underutilized because parents fear the possibility of adverse events. There is 
no knowledge whether caregivers would be willing to pay (WTP) for safe and 
effective medications in general.  
Material and Methods: In a conjoint analysis, the status quo and hypothetical 
treatment options are defined by four attributes: Episode-free days, risk of 
exacerbation, information available on the long-term impact of the treatment, and out-
of-pocket expenses. Based on random utility theory, a binary purchase decision 
equation is specified and estimated using probit. Several tests were performed with 
regards to the scaling of the attribute variables, the linearity of the utility function 
used, and the derivation of a final model.  
Results and conclusions: Marginal willingness-to-pay per month for 20 additional 
episode free days due to a new treatment turns out to be US$ 6.00. An interesting 
question from the (industry) policy point of view for possible new products is the 
amount of WTP for the product as a whole. Assuming that the final model is correctly 
specified, the (negative) constant may be interpreted as indicating that caregivers 
feel confident with the asthma treatment options already on the market and having 
hence not a positive relation to a new treatment. 
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Introduction 
Asthma is a chronic disease that effects between 9 and 12 million persons in the 
United States [1] and is the most common chronic disease of childhood [2]. Nearly 5 
million children in the United States are affected by asthma, which is more than 5 
percent of the population younger than 18 years [3]. Asthma is the leading cause of 
lost school days in children [4, 5]. In children four years or younger, its prevalence 
increased 160 percent from 1980 to 1994. There are several effective drugs that 
relieve the symptoms of asthma, and more are currently being developed. However, 
compliance is far from perfect because parents as caregivers fear the possibility of 
adverse drug reactions. The objective of this study is to measure the importance of 
these concerns in comparison with the benefits of treatment using willingness-to-pay 
(WTP) estimates derived from a discrete-choice experiment (DCE). 
For an economic evaluation (such as a discrete-choice analysis) of treatments in 
diseases such as asthma, where a substantial impact is on quality of life rather than 
survival, it is crucial to be able to incorporate the effects of the new therapies on 
quality of life and include those effects in the economic evaluation. Since there are 
many health insurances in the US that have a co-payment rate for the insured in their 
contract, considerations of relative effectiveness could be complemented by WTP 
estimates. Within health care there is substantial evidence to suggest that, in addition 
to the treatment outcome (that is, the effectiveness), other aspects of the process of 
receiving treatment are also important for individuals [6, 7, 8, 9]. The present study is 
analyzing hypothetical products for the treatment of (pre-school) asthma defined by 
four attributes. The target population is children with a maximum age of 4 years. 
Obviously the possibility to ask the children themselves was naturally limited and 
hence the caregivers answered for them.  
The purpose of this study is to calculate, using discrete choice analysis, the 
willingness-to-pay of caregivers with asthmatic children for different (hypothetical) 
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treatments defined by four attributes. Additionally the marginal willingness-to-pay for 
an improvement in efficacy (episode free days) was analyzed. Furthermore the 
analyses were done for the whole study cohort as well as for various risk averse 
groups.  
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Materials and Methods 
The DCE1 performed in this study rests on Lancaster’s theory of demand [10], with 
states consumer value not so much the quantities of consumer goods but their 
qualities and attributes. In the present context the consumer is a caregiver of at least 
one asthmatic child with the age of less than four years, and the commodities in 
question are treatment options defined by four attributes. Thus the preferences of 
caregivers substitute for those of their patients (which would have been far more 
difficult to investigate). Caregivers were asked to choose between pairs of asthma 
treatments for their child, viz. a fixed status quo and a new (hypothetical) alternative 
whose attribute levels changed in the course of the DCE. Attributes and their levels 
were pre-tested in face-to-face interviews with six caregivers in the autumn of 2005.  
Table 1: Characteristics of individuals from the pre-test 
n = 6 caregivers Percent 
Cumulative 
Percent 
Gender   
     Female 83.3  
Age   
     < 35 years 66.6  
     > 35 years 33.3 100 
Number of children < 4 years   
     1 child 50  
     2 children 50 100 
Most important attributes   
     Efficacy (episode free days) 83.3  
     Ease of handling 50  
     Side effects (exacerbation) 100  
     Long-term information available  83.3  
     Out-of-pocket expenses 83.3  
     Number of administrations per day 66.6  
     Time for administration 66.6  
 
Original attributes were ease of handling, efficacy (episode-free days), time for 
administration of treatment, number of administrations per day, side effects (risk of 
asthmatic exacerbation), information on long-term effects in children between 4 and 
                                                 
1 The study protocol was conducted in accordance with the Declaration of Helsinki and approved by 
local ethics committees, and all caregivers gave written informed consent. 
 Stefan Walzer – 5 Essays in Health Economics 60 
14 years of age (provided by the FDA) and out-of-pocket cost. The presence or 
absence of side effects (EXACERBATION) was deemed important without exception 
(see table 1). The other retained attributes are episode free days (FREEDAYS), 
available information provided by the FDA (INFORMATION), and the out-of-pocket 
cost of the treatment (EXPENSE). 
Table 2: Product attributes and levels retained in the main survey 
Attributes Label Levels Value labels 
Episode free days FREEDAYS Increase from 180 to 200 episode 
free days per year 
200 
  Increase from 180 to 220 episode 
free days per year 
220 
  Decrease from 180 to 160 episode 
free days per year 
180 
  Decrease from 180 to 140 episode 
free days per year 
140 
Exacerbation EXACERBATION Risk of EXACERBATION: 6% of 
patients develop a mild to severe 
EXACERBATION 
6 
  Risk of EXACERBATION: 10% of 
patients develop a mild to severe 
EXACERBATION 
10 
  Risk of EXACERBATION: 16% of 
patients develop a mild to severe 
EXACERBATION 
16 
Information about long-
term effects by the FDA 
available 
INFORMATION INFORMATION available on long-
term effects in children between 4 
years and 14 years of age 
1 
  No INFORMATION available on 
long-term effects in children 
between 4 years and 14 years of 
age 
2 
Out-of-pocket 
EXPENSES 
EXPENSES $10 per month 10 
  $30 per month 30 
  $50 per month 50 
 
The levels of attributes were defined as follows (see table 2). FREEDAYS, 
symbolizing the change in the number of episode-free days from a baseline value of 
180 days per year [14]. Increases are to 200 and 220 days, decreases, to 160 and 
140 days, respectively. EXACERBATION varies between 6%, 10% and 16%, 
indicating the share of patients who develop mild to severe exacerbation. A recent 
study with adults has shown that mild to moderate asthmatic exacerbation causes a 
marked decrease of well-being [15]. This is assumed to hold true in pre-school 
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children. As to INFORMATION on long-term effects specifically in children between 4 
and 14 years of age, a study has found that caregivers are concerned if this 
information is locking. about the missing long-term effects of asthma treatment in pre-
school children [17]. Finally EXPENSES ranges from $10, $30 to $50. Status quo 
treatment (see table 3) was defined as having 180 episode-free days per year and a 
10 percent risk developing mild to severe exacerbation of asthma with information 
provided by FDA and monthly out-of-pocket cost of $20. 
Table 3: Status quo treatment – definition by attribute levels 
Attributes Levels 
Episode free days 180 episode free days per year 
EXACERBATION Risk of EXACERBATION: 10% of patients 
develop a mild to severe EXACERBATION 
INFORMATION availability INFORMATION available on long-term effects 
in children between 4 years and 14 years of 
age 
Out-of-pocket EXPENSES $20 per month 
 
Since these attributes have 4, 3, 2 and 3 levels, respectively the number of scenarios 
amounts to a total of 72 (= 4*3*2*3). This number would cause interviews of 
excessive length. Using the ORTHOPLAN procedure of SPSS, the design was 
reduced to 16 scenarios while this still permits to infer utility values for all 
combinations of attribute levels [13]. All study participants had to answer these 16 
variants, whose sequence was randomized to avoid possible ordering bias [17]. Each 
time respondents had to indicate whether or not they preferred the treatment or the 
status quo (for a sample card presented to study participants, see Appendix A.1). 
Due to financial constraints, only 42 respondents were included in the study. 
However, to test the validity and significance of parameter estimates, a Monte-Carlo 
simulation yielding comparison estimates was also performed. The survey was 
conducted online in February 2006. The questionnaire also covered socioeconomic 
characteristics, subjective health status (chronic or other diseases) of the caregiver, 
specifics of the asthma treatment, and diagnosis of the physician.  
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Choices of caregivers are hypothesized to be governed by a common utility function, 
( )kk ZUU = , where Uk denotes their utility in scenario k, which depends on Zk, the 
vector of attribute values pertaining to k. Any alternative, which may affect choice, is 
included in the vector of measured attributes z ε Z [11]. For instance, the change in 
the number of episode-free days from the status quo constitutes an element of the 
attribute vector.  
Since income Y and out-of-pocket cost pk determine the number of units xk of the 
good that can be purchased, maximum attainable utility not only depends on permit 
attributes but income and prices. Thus the indirect utility function can be written, 
( ) [ ]*,, kkkk ZUYpzVV ==         (2) 
The marginal rate of substitution between two attributes m and n is given by the ratio 
of marginal utilities, which indicates the relative subjective importance of them, 
knk
kmk
zV
zV
MRS
∂∂
∂∂
=
/
/
 (3). 
If the variable n in Equation (3) is assumed to be price in the presented context, this 
can be interpreted as the marginal willingness-to-pay for attribute m.  
A vector of socioeconomic characteristics h is introduced into the function to reflect 
the variability of tastes across the population to which the model of choice behavior 
applies [12], ( )hYpzVV kkk ,,,=        (4) 
It is assumed that the chosen treatment maximizes the individual’s utility, in keeping 
with the theory of homus economicus [11]. However, to the observer the 
determinants of utility are never fully known causing behavior to seemingly have a 
random component. Accordingly, the choice probability of alternative k is equal to the 
probability that the (indirect) utility of alternative k, Vk, is greater than or equal to the 
utility of alternative q, 
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( ) ( )qk VVk >= PrPr ,         (5) 
where Pr(k) is the probability of the caregiver choosing alternative k. In general, the 
random utility of an alternative can be expressed as a sum of observable (or 
systematic) and unobservable components [13], 
( ) kkkkkk WSYpzWV εε +≡+= ,,,        (6) 
With this result, equation (5) can now be rewritten as 
( ) ( ) ( )kqkqqqkk WWWWk εεεε +−>=+>+= PrPrPr     (7) 
Therefore the random element must be dominated by systematic differences in utility. 
For further analysis it is assumed that the error term (εq – εk) is standard normally 
distributed. With this assumption, the Probit model can be applied to estimate Pr(k). 
Furthermore, assuming the indirect utility function to be additively separable, the 
determinants of V that do not differ between scenarios q and k (in particular Y and S) 
drop out of the equation. 
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Results 
Descriptive statistics 
In table 4, descriptive statistics of the caregivers with regard to the dependent and 
explanatory variables are reported. Of all caregivers participating in this study, 19% 
came from the Eastern United States, 33% from the Midwest, 35% from the South 
and 11.9% from the West. Nearly all caregivers who took part in the survey are 
female (92.9%), while 7% of caregivers are fathers or grandparents. The 
respondents on average have one child. 40% were working full-time and 45% were 
homemakers. Most of the study participants reported not to smoke (71.4%), whereas 
16.7% reported to smoke about one pack of cigarettes per day. The reason for the 
high proportion of non-smokers is to be found in the fact that the majority of 
caregivers have also diagnosed asthma (92.9%) or wheezing conditions (28.6%).  
Caregivers were also asked how confident they are in knowing what they do when 
thinking about their overall ability to take care of their family’s general health – eating 
right, getting check-ups, taking medicine, and deciding when to see the doctor. The 
median for this is 3.5 (standard deviation of 0.89), with 1 equivalent to “not at all 
confident” and 5 “Extremely confident”. Overall 42.9% of respondents agreed with the 
feeling “very confident” (rating of 3), and another 26.7% agreed with feeling 
”extremely confident” (rating of 4). There, 31% felt fairly or somewhat confident, while 
69% felt very or extremely confident. These descriptive findings suggest that 
administration of drugs to the children should be relatively good. 
In 18% of cases, physicians never told the caregiver the diagnosed severity of their 
child with asthma. Thus, while 21.4% of caregivers rated the severity of their child as 
very mild, no physician gave the condition this low rating, likewise 4.8% of all cases, 
physicians diagnosed the children as having severe asthma, compared to 2.4% of 
caregivers. 
Caregivers were also asked to estimate the frequency with which caregivers (in 
general) forget to administrate the medication to their child during a week due to 
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several reasons (job stress, care for other children, etc.). In various studies, this 
estimate is as high as 95% (with an average around 50%), [18, 19] respondents 
estimated that 16.7% of caregivers never forget during a week. However, when 
asked about their own failure, 88.1% say they forget themselves in 19% of all cases.  
The characteristics of the children were as follows. Anyway the first born, 33% are 
male and have a mean age of four years. Anyway, the second born, 64.3% were 
male and had a mean age of 2.8 years (standard deviation 0.96). Notice also that 
children with diagnosed asthma have a higher probability of having allergies in 
comparison to the average of the same age [19]. In  this sample, 88% of children 
have diagnosed asthma, 26% wheezing conditions, and 71% have allergies. 
Table 4: Descriptive Statistics of caregivers and their children between 0 and 4 years 
 Percent Cumulative Percent 
Gender   
     Female 92.9  
Age   
     <30 years 28.6  
     30 – 39 years 42.8 71.4 
     40 – 49 years 19.1 90.5 
     >50 years 9.5 100 
Number of children < 4 years   
     1 child 73.8  
     2 children 26.2 100 
Rating of health care   
     Fairly/somewhat confident 31.0  
     Very/extremely confident 69.0 100 
Number of children with diagnosed 
asthma and/or wheezing conditions 
  
     1 child 73.8  
     2 children 26.2 100 
Regions   
     East 19.0 19.0 
     Midwest 33.3 52.4 
     South 35.7 88.1 
     West 11.9 100 
Relationship to children   
     Mother or female guardian 85.7  
     Father or male guardian 7.1 92.9 
     Grandparent 7.1 100 
Level of education   
     High school graduate (or lower) 11.9  
     Some college 31.0 42.9 
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     Associate / Bachelor’s degree 40.5 83.3 
     Postgraduate school 14.3 97.6* 
Current employment situation   
     Working full-time 40.5  
     Working part-time 11.9 52.4 
     Homemaker 45.2 97.6** 
Annual household income in 2004   
     < US$25,000 4.8  
     US$ 25,000 – 49,999 45.2 50.0 
     US$ 50,000 – 74,999 19.0 69.0 
     > US$ 75,000 23.8 92.9*** 
Non-Smoker 71.4  
Severity estimation by caregiver   
     Very mild 21.4  
     Mild 35.7 57.1 
     Moderate 40.5 97.6 
     Severe 2.4 100 
Severity diagnosis by physician   
     Mild 35.7  
     Moderate 40.5 76.2 
     Severe 4.8 81.0 
     Doctor never told me the severity 19.9 100 
Compliance estimation for other 
caregivers 
  
     < 20% 54.8  
     20% - 39% 23.8 78.6 
     40% - 59% 7.1 85.7 
     > 60% 14.3 100 
Own compliance estimation   
     < 10% 76.2  
     10% - 19% 11.9 88.1 
     20% - 29% 4.8 92.9 
     > 30% 7.1 100 
Children characteristics Percent Cumulative Percent 
Age   
     < 2 years (child 1) 33.3  
     < 2 years (child 2) 0  
Gender   
     Female (child 1) 35.7  
     Female (child 2) 66.7  
Race   
     White 88.1  
     Black 4.8 92.9 
     Other 7.1 100 
Number of asthma attacks in the 
least 4 weeks 
  
     Never 85.7  
     A few days 9.5 95.2 
     Some/Most days 4.8 100 
Prevalence of asthma 88.1  
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Prevalence of wheezing conditions 26.2  
Prevalence of allergies 71.4 -- 
* Other education: 2.4%; ** Retired: 2.4%; *** Declined to answer: 7.1% 
 
Model specification 
Since 16 different asthma treatment decisions had to be evaluated by each 
respondent, the data are of the panel type. For this reason, a random effects probit 
model is used, assuming responses of a given individual to purchase questions to be 
correlated, while answers provided by different individuals to be uncorrelated.  
The first specification test was done on the scaling of the variables reflecting product 
attributes. The scaling issue concerns three product attributes, the episode free days 
(FREEDAYS), the exacerbation probability (EXACERBATION), and the out-of-pocket 
expenses (EXPENSES). The discussion will focus on FREEDAYS, dealing with 
EXACERBATION and EXPENSES more concisely. The efficacy in terms of episode 
free days was scaled using two better outcomes than the status quo (180 days) and 
two worse outcomes: 200 and 220 for the better outcomes and 160 and 140 for the 
worse one. However, a linear representation of product attributes would simplify the 
calculation of the marginal willingness-to-pay (MWTP) values considerably. The 
evidence suggests that a linear representation of FREEDAYS is compatible with the 
data, as the effect of a reduction in episode free days from 180 to 160 days cannot 
be statistically distinguished from the increase in episode free days from 180 to 200 
days. Also, episode free days reductions from 180 to 140 days and the improvement 
from 180 to 220 days have the same effect close to 22% according to the data. 
Therefore, the linear representation of FREEDAYS may be retained, permitting the 
construction of an average value of FREEDAYS and hence the calculation of MWTP 
at the sample means. The same tests for linearity were used for the product 
attributes EXACERBATION and EXPENSES. Results clearly suggest that a linear 
representation of all parameters is compatible with the data. A popular alternative is 
the quadratic utility function [20]. Therefore, the linearity of the coefficients was 
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analyzed by the Wald test. In view of the orthogonal design imposed, the utility 
function to be tested contained no interaction terms [21]. Results indicated that the 
quadratic terms were not significant at conventional levels, with the one exception of 
expenses. However, the estimated coefficient of (EXPENSES)2 turned out so small 
as to make the linear alternative, evaluated at the mean cost, indistinguishable from 
the quadratic. A likelihood ratio test indicated that the exclusion of all quadratic terms 
does not entail a significant loss of explanatory power. Therefore, an indirect utility 
function linear in product attributes seems to serve as a sufficient local approximation 
to its true counterpart (which merely needs to be quasiconvex in price). 
Up to this point, the specification tests involved only the product attributes because 
individual characteristics should be irrelevant in the choices analyzed if the utility 
function is assumed to be additively separable in product attributes and socio-
economic characteristics. To test this assumption a model was estimated including 
interaction terms between socioeconomic variables and EXPENSES. From an 
economic point of view this can be justified since these interaction terms reflect the 
marginal utility of money, which varies with personal characteristics [22]. However, all 
interaction terms lacked statistical significance. In addition a likelihood ratio test 
indicated clearly that including interaction terms does not improve goodness of fit of 
the model. This finding is in agreement with the assumption of a utility function which 
is additively separable.  
Table 5: Random effects probit estimates for the final model 
Variable Coefficient Standard error z P>|z| 
FREEDAYS .0069* .0024 2.85 0.004 
EXACERBATION -.0109 .0117 -0.93 0.351 
INFORMATION -.3447** .1039 -3.32 0.001 
EXPENSES -.0232*** .0036 -6.51 0.000 
CONSTANT -.7936 .4990 -1.59 0.112 
Number of observations 756    
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Chi² (4) 52.48    
Prob > chi² 0.0000  Rightly 
predicted: 
0.677 
   * (**, ***) Coefficient different from zero with an error probability of 5% (1%, 0.1%). 
 
The estimates of the final random effect probit model (which contains only the four 
product attributes in linear form, including EXPENSES) are presented in table 5 for 
the original data. All product attributes are highly significant but EXACERBATION 
and the constant. This is of particular interest since the attribute exacerbation was 
one of the four most important attributes in the pre-test interviews. One possible 
reason why this attribute is non significant is the low number of respondents. Due to 
budget restrictions, only 42 respondents could be included in the survey. However, to 
improve the validity and significance of the study the data have also been simulated 
by 100 Monte-Carlo iterations. For this the binomial distribution was assumed for the 
simulation of the outcome “Scenario”. For the caregiver’s socio-economic 
characteristics a beta-pert distribution was assumed to stay within the calculated 
ranges of the parameters given by the study participants [23]. It turned out that also 
the attribute EXACERBATION is highly significant when using 100 iterations (see 
table 6), which was used as having 100 respondents.  
Table 6: Random effects probit estimates for the simulated data (100 Monte-Carlo iterations) 
Variable Coefficient Standard error z P>|z| 
FREEDAYS .0078*** .0016 4.92 0.000 
EXACERBATION -.0283** .0086 -3.28 0.001 
INFORMATION -.5011*** .0702 -7.14 0.000 
EXPENSES -.0216*** .0023 -9.53 0.000 
CONSTANT -.5264 .03134 -1.68 0.093 
Number of observations 1600    
Chi² (4) 142.48    
Prob > chi² 0.0000  Rightly 0.689 
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predicted: 
* (**, ***) Coefficient different from zero with an error probability of 5% (1%, 0.1%). 
 
Willingness-to-pay 
The calculation of MWTP for an improvement or reduction of episode free days is 
based on Equation (3). Since the indirect utility function is linear in its arguments, the 
marginal rate of substitution between the change in episode free days and the out-of-
pocket expenses for a treatment of caregiver’s child amounts to a division of the 
regression coefficient pertaining to FREEDAYS by the coefficient pertaining to 
EXPENSES.  
MWTP per month for 20 additional episode free days due to a new treatment turns 
out to be US$6.00 (=-0.0069/-0.0231). A standard prediction in the theory of health 
economics is that individuals with a higher risk aversion should have a higher MWTP 
for a better outcome like an improvement of episode free days [24]. However as 
explained before, risk aversion is one of the personal characteristics that should not 
influence the decision.  
 
An interesting question from the (industry) policy point of view for possible new 
products is the amount of WTP for the product as a whole. Assuming that the final 
model is correctly specified, the (negative) constant may be interpreted as indicating 
that caregivers feel confident with the asthma treatment options already on the 
market and having hence not a positive relation to a new treatment. From this 
benchmark, one may integrate the MWTP over the four attributes distinguished to 
obtain WTP for the product as a whole. As shown in table 8, a treatment having 
average features with regard to each of the three attributes distinguished evokes a 
small but positive WTP (US$1.65). The attributes for this average product is defined 
as having no improvement in episode free days, a probability of 6% to develop an 
exacerbation and information available by the FDA. The maximum WTP (US$13.54) 
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for a new asthma treatment could be achieved with a maximum of improvement in 
episode free days (220 days per year), 6% probability of exacerbation and 
information available by the FDA. Out of the 16 variants described, one fourth of the 
treatment options have a positive average WTP. The negative WTP observed raises 
the issue of future product development and provision of information to potential 
users. As can be gleaned from table 8, one increment on the scale of FREEDAYS (4 
levels) is worth US$0.30 (=0.0069 / 0.0232). This means that a status quo of 180 
episode free days [14] lead to WTP of US$53.53 with everything else held constant. 
In the case of EXACERBATION, this figure amounts to a negative amount of 
US$0.47 per percentage point of exacerbation probability. The available information 
from the FDA is worth US$14.86. Therefore, assuming equal productivity of R&D 
efforts, these efforts should be directed at improved efficacy (episode free days). 
Also, information about improvements and safety may prove of particular importance 
for encouraging the purchase and use of (new) asthma treatments for children. 
Table 7: Willingness-to-pay (WTP) for specified asthma treatments in US$ 
 WTP for a specified 
asthma drug in US$ 
Attributes (FREEDAYS, EXACERBATION, 
INFORMATION) 
Mean WTP 1.65 180 / 6 / 1 
Maximum WTP 13.54 220 / 6 / 1 
Minimum WTP -29.80 140 / 16 / 2 
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Discussion and Conclusion 
To the best of our knowledge this study is the first one, which analyzed the impact of 
various treatment attributes on the willingness-to-pay of caregivers for their pre-
school children. Obviously the sample size is relatively small due to budget 
restrictions, however the results should be important in the rating of willingness-to-
pay and utility estimations in pre-school children in chronic diseases such as asthma. 
Due to the fact that individuals have difficulties when dealing with probabilities [25], 
the measurement of the MWTP for an improvement in episode free days (using 
probability) may lead to particular challenges. First, the individuals concerned 
probably are not only interested in the aspect of the change in efficacy (assumed to 
be episode free days) but may consider other aspects of asthma treatment, such as 
the possibility to develop an asthmatic exacerbation or available information by the 
FDA (information on long-term effects in children between 4 and 14 years of age) as 
well as expenses. Secondly, the population of interest is of low age (between 0 and 4 
years), which leads to the fact that these could not be included in the study due to 
natural limitations. Hence the caregivers of the target population were included in the 
survey as an approximation. This assumption could be verified due to the fact that 
the caregivers must decide which treatment (if any) should be offered to their child 
and to which price. Additionally it can be assumed that caregivers also want to 
maximize the utility (and quality of life) of their child.  
Conjoint analysis requires respondents only to indicate whether they prefer one 
scenario over another. Moreover, it was possible to use the status quo as the 
reference scenario. Based on random utility theory, a binary purchase decision 
equation was specified and estimated using probit. Several tests were performed 
with regards to the scaling of the attribute variables, the linearity of the utility function 
used, and the derivation of a final model.  
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Appendix 
 
Appendix A.1: Example of a card presented to respondents 
 AGENT A AGENT B 
Episode free days 180 episode free days per 
year 
220 episode free days per year 
Exacerbation Risk of exacerbation: 10% of 
patients develop a mild to 
severe exacerbation 
 
Risk of exacerbation: 16% of 
patients develop a mild to 
severe exacerbation 
 
Information availability Information available on 
long-term effects in children 
between 4 years and 14 
years of age 
 
Information available on long-
term effects in children 
between 4 years and 14 years 
of age 
 
Out-of-pocket expenses $20 
 
$50 
 
   
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Abstract 
Background: The purpose of this study was to evaluate, using conjoint analysis and 
utility rating scale from 0 to 10 separately, asthma patients’ preferences for different 
aspects of asthma treatment and the possible existence of learning effects. 
Methods: For conjoint analysis a status quo treatment and hypothetical treatment 
options were defined by four attributes. The respondents were asked, after they 
decided which treatment options they have chosen, how they would rate the 
importance of their decision. 
Results: The utility scores derived for each scenario were relatively stable and lying 
between a value of 7.095 and 7.929. Only for one scenario the mean utility was 
estimated higher whereas the explanation for this outlier could be found in the 
characteristics of that treatment option, which was nearly a perfect treatment option 
and hence the utility score is higher than for the other products. 
Discussion: It turns out that the influence of the product attributes on the score 
rating was statistically not significant. Even in the three scenarios where it could be 
shown that the attributes have a statistically significant influence two of the four 
attributes showed collinearity between each other. Findings of the correlation 
analyzes could be interpreted as a learning effect between the utility score and the 
scenario decisions made before.  
Conclusions: Utility scores could be applied for studies, where just the overall utility 
for a given treatment is of interest, but as far as the product attributes are of 
particular interest for the utility estimation, conjoint analysis should be used. 
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Introduction 
For an economic evaluation of treatments in diseases such as asthma, where a 
substantial impact is on quality of life rather than survival, it is crucial to be able to 
incorporate the effects of the new therapies on quality of life and include those effects 
in the economic evaluation. To evaluate the utilities of patients for various treatment 
options several possibilities are available such as rating scales, standard gamble, 
time tradeoff or conjoint analysis [1, 2, 3]. Conjoint analysis was originally developed 
for market research into consumer preferences, and is a method that investigates the 
relative importance of groups of attributes, e.g., products with certain properties or 
more abstract concepts such as treatment procedures [4, 5]. It has been applied to 
various aspects of health care; for reviews, see Ryan 1996 [6] or Szeinbach et al. 
1999 [7]. Usually researchers are just using one of the above mentioned evaluation 
methods to derive utilities. The purpose of this study was to evaluate, using conjoint 
analysis and utility rating scale from 0 to 10 separately, asthma patients’ preferences 
for different aspects of asthma treatment, including efficacy (episode free days), side 
effects (risk of exacerbation), availability of information by the FDA about long-term 
effects, and out-of-pocket expenses. Additionally the possibility of the existence of 
learning effects within the study participants within the answers for the different 
scenarios was analyzed.  
The target population of this study is pre-school children with a maximum age of 4 
years. Obviously the possibility to ask the children themselves was naturally limited 
and hence the caregivers answered for them. The relation between the utility 
derivation methods was analyzed and conclusions for further economic evaluations 
were done. 
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Methods 
It is assumed that the preferences of caregivers of pre-school children with asthma 
could be taken as approximations for the utility of their child for a given treatment. For 
the present analysis caregivers were asked to choose between two hypothetical 
asthma treatments for their child. The decision was based on a status quo treatment 
versus a new (hypothetical) treatment with changed attribute levels. After this 
decision the caregivers chose a utility value for the chosen treatment option from a 
score range of 0 to 10, whereas 0 was assumed to be the worst outcome and 10 the 
best possible. 
 
Conjoint analysis 
The levels of attributes were defined as follows (see table 1):  
Table 1: Product attributes and levels retained in the main survey 
Attributes Label Levels Value labels 
Episode free days 
FREEDAYS Increase from 180 to 200 episode 
free days per year 
200 
  Increase from 180 to 220 episode 
free days per year 
220 
  Decrease from 180 to 160 episode 
free days per year 
180 
  Decrease from 180 to 140 episode 
free days per year 
140 
Exacerbation EXACERBATION Risk of EXACERBATION: 6% of 
patients develop a mild to severe 
EXACERBATION 
6 
  Risk of EXACERBATION: 10% of 
patients develop a mild to severe 
EXACERBATION 
10 
  Risk of EXACERBATION: 16% of 
patients develop a mild to severe 
EXACERBATION 
16 
Information about long-
term effects by the FDA 
available 
INFORMATION INFORMATION available on long-
term effects in children between 4 
years and 14 years of age 
1 
  No INFORMATION available on 2 
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long-term effects in children 
between 4 years and 14 years of 
age 
Out-of-pocket 
EXPENSES 
EXPENSES $10 per month 10 
  $30 per month 30 
  $50 per month 50 
 
‘Episode free days’ (FREEDAYS), symbolizing the change in the risk to develop 
asthma attacks from an unknown individual level, takes on changes from 180 days 
(baseline [8]) to 200 and 220 days per year as well as a possible decrease in change 
to 160 and 140 days per year. ‘Exacerbation’ (EXACERBATION) varies between 
levels of 6%, 10% and 16% of patients who develop mild to severe exacerbation. For 
the FDA ‘information’ (INFORMATION) on long-term effects in children between 4 
and 14 years of age two levels were used: Availability or non availability. The monthly 
‘out-of-pocket cost’ (EXPENSES) ranges from $10, $30 to $50. Status quo treatment 
(see table 2) was defined as having 180 episode free days per year and a risk to 
develop a mild or severe exacerbation of 10%. Information by the FDA is available 
and the monthly out-of-pocket expenses are $20. Detailed information about the 
preference study itself was recently published [9, 10]. 
Table 2: Status quo treatment – definition by attribute levels 
Attributes Levels 
Episode free days 180 episode free days per year 
EXACERBATION Risk of EXACERBATION: 10% of patients 
develop a mild to severe EXACERBATION 
INFORMATION availability INFORMATION available on long-term effects 
in children between 4 years and 14 years of 
age 
Out-of-pocket EXPENSES $20 per month 
 
The conjoint analysis can be derived from Lancaster’s theory of demand [11]. There 
the consumer values the quantity of product attributes at his disposal through the 
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purchase of a commodity. In our case the consumer is a caregiver of at least one 
asthmatic child with the age of less than 4 years.  
According the theory of homus economicus it is assumed that the chosen product, or 
in this study the chosen treatment, maximizes the individual’s utility [12]. However, to 
the observer the utilities are not known with certainty and are therefore treated as 
random variables. Accordingly, the choice probability of alternative k is equal to the 
probability that the (indirect) utility of alternative k, Vk, is greater than or equal to the 
utility of alternative q:  
( ) ( )qk VVk >= PrPr          
 (1) 
where Pr(k) is the probability of the decision maker choosing alternative k. In general, 
the random utility of an alternative can be expressed as a sum of observable (or 
systematic) and unobservable components of total utilities [13]: 
( ) kkkkkk WSYpzWV εε +≡+= ,,,        
 (2) 
With this result equation (1) can now be rewritten as 
( ) ( )
( ) ( )kqkq
qqkk
WWk
WWk
εε
εε
+−>=
+>+=
PrPr
PrPr
       
 (3) 
For further analysis it is assumed that the error term ε is standard normal distributed. 
With this assumption the probit model can be applied to estimate Pr(k). Furthermore 
assuming the indirect utility function to be additively separable, the determinants of W 
that do not differ between scenarios q and k drop out of the equation [10]. 
 
Utility (rating) score 
The typical rating score is shown as a line with well-defined endpoints, whereas the 
extreme outcomes (e.g. death and perfect health) are shown at the end of the line. In 
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this study the respondents were asked after they decided which treatment options 
they have chosen how they would rate the importance (in terms of utility) of their 
decision. 
The rating score is relatively easy to apply and could be well understood by study 
participants. However there are various limitations in this method. First of all the utility 
score is not related to any decision and hence not related to any attribute evaluation. 
Therefore there is no theoretical basis with which the results could be interpreted as 
cardinal utility values. But for a quality index it is not enough to know the ordinal utility 
values for the single treatment options, or more general for the different health states. 
It is also important to know the differences between the utility values [2]. Furthermore 
the rating scale is sensitive for different biases [14] such as the end-of-scale bias. 
There the respondents are not willing to set the utility value in the next location to the 
extreme values. Another possible bias could be that individuals range their answers 
on the whole scale (spacing-out bias). 
However it is assumed that the treatment options the caregivers have chosen in the 
various scenarios is maximizing their utility and hence the utility score could be taken 
as an approximation for their real utility of that chosen option. Of course no utility 
calculations can be done for other treatment options than the 16 offered to the 
individuals and also no computations could be done for the rejected treatment 
option(s). 
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Results 
Descriptive statistics 
The target population of this study is pre-school children with a maximum age of 4 
years. Obviously the possibility to ask the children themselves was naturally limited 
and hence the caregivers answered for them.  
Table 3: Descriptive Statistics of caregivers and their children between 0 and 4 years (more detailed in 9,10) 
 Percent Cumulative Percent 
Gender   
     Female 92.9  
Number of children < 4 years   
     1 child 73.8  
     2 children 26.2 100 
Rating of health care   
     Fairly/somewhat confident 31.0  
     Very/extremely confident 69.0 100 
Children characteristics Percent Cumulative Percent 
Age   
     < 2 years (child 1) 33.3  
     < 2 years (child 2) 0  
Gender   
     Female (child 1) 35.7  
     Female (child 2) 66.7  
Cough in last 4 weeks   
     Never 14.3  
     A few days 31.0 45.3 
     Some days 23.8 69.1 
     Most days 19.0 88.1 
     Every day 11.9 100 
Wheezing conditions in last 4 weeks   
     Never 26.2  
     A few days 33.3 59.5 
     Some days 35.7 95.1 
     Every day 2.4 97.6**** 
Shortness of breath in last 4 weeks   
     Never 57.1  
     A few days 16.7 73.8 
     Some days 19.0 92.8 
     Most of the days 4.8 97.6**** 
Asthma attacks in last 4 weeks   
     Never 85.7  
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     A few days 9.5 95.2 
     Some days 2.4 97.6 
     Most of the days 2.4 100 
Number of asthma attacks in last 4 
weeks 
  
     0 16.7  
     1 attack 50.0 66.7 
     2 attacks 16.7 83.3 
     6 attacks 16.7 100 
Awakened in last 4 weeks due to 
asthma/wheezing conditions 
  
     Never 38.1  
     A few days 40.5 78.6 
     Some days 16.7 95.2 
     Most of the days 4.8 100 
* Other education: 2.4%; ** Retired: 2.4%; *** Declined to answer: 7.1% 
**** Don’ know: 2.4% 
 
In table 3, some descriptive statistics of the caregivers with regard to the dependent 
and explanatory variables are reported. The whole descriptive statistics were recently 
published [9, 10]. Nearly all caregivers who took part in the survey were female 
(92.9%). The average of respondents has one child. Caregivers were also asked how 
confident they are in knowing what they do when they are thinking about their overall 
ability to take care of their family’s general health – eating right, getting check-ups, 
taking medicine, deciding when to see the doctor. Within the whole population 42.9% 
agreed with the statement feeling “Very confident” and another 26.7% agreed with 
the statement feeling ”Extremely confident”. Summarized 31% felt fairly and/or 
somewhat confident and 69% of caregivers felt very and/or extremely confident.  
During the last 4 weeks in advance of the survey 23.8% of children have had 
experienced cough on some days whereas 19% experienced this complication most 
days. 11.9% of children experienced cough every day. The condition wheezing was 
less often experienced every day (2.4%) but nearly 33% have experienced wheezing 
a few days in the last 4 weeks. Caregivers reported that 57.1% of their children never 
had shortness of breath but also 19% reported that their children experienced that 
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symptom some days in the last month. Asthma attacks in this study population were 
not that frequent (never experienced in the last 4 weeks: 85.7%) with experiences of 
this symptom a few days in 9.5%. Anyway of those who experienced asthma attacks 
50% had one attack in the last month, 16.7% had two and another 16.7% had six 
asthma attacks. The possibility of awaken during the night due to asthma/wheezing 
conditions, such as asthma attacks, etc., was relatively frequent but not that severe: 
38.1% never awakened, 40.5% awakened a few nights, 16.7% some nights but also 
4.8% awakened each night. 
 
Conjoint analysis 
Results from the discrete choice decisions served as a basis for a conjoint analysis 
[12]. Relative importance for each product attribute as well as utility estimations for 
each attribute level were calculated. 
For the caregivers the key attribute for an asthma drug for the treatment of childhood 
asthma is FREEDAYS. On a scale from 0 to 100 this attribute got the calculated 
relative importance of 44.2 (see figure 1). In contrast to this finding is the relative 
importance of the attribute EXACERBATION, which only reached 16.2, which is the 
most unimportant attribute of the attributes offered. Even the variable INFORMATION 
available on long-term effects in children between 4 years and 14 years of age was 
more important than the side effects (19.2). Out-of-pocket expenses per month were 
the second most (relative) important attribute, whereas it was only slightly more 
important than the attribute INFORMATION (20.5). 
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Figure 1: Relative importance of Factors for Treatment of Pediatric Asthma and/or Wheezing Conditions 
 
Utility (rating) score 
The utility scores for each of the 16 scenarios had nearly the same descriptive 
statistics in terms of mean and standard deviation (see table 4), which supports the 
finding of an end-of-scale bias [14].  
Table 4: Descriptive Statistics of Utility estimations derived from a utility rating score 
 Mean Standard deviation 
Utility 1 7.2857 2.3919 
Utility 2 7.1429 2.2039 
Utility 3 7.0952 1.9607 
Utility 4 7.1429 2.0668 
Utility 5 7.3333 1.9464 
Utility 6 7.5952 1.9885 
Utility 7 7.1905 2.0271 
Utility 8 7.3810 1.9625 
Utility 9 7.6905 2.0301 
Utility 10 7.6191 1.8604 
Utility 11 7.9286 1.9556 
Utility 12 7.1667 1.7379 
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Utility 13 7.7381 1.8878 
Utility 14 8.4762 1.7564 
Utility 15 7.5714 1.8500 
Utility 16 7.2857 2.0752 
 
There the respondents are not willing to set the utility value next to an extreme value. 
The mean turns out to be in the range of 7.095 and 7.929 with one exception for 
scenario 14 with a mean of 8.476. The explanation for this outlier could be very easily 
found in the characteristics of that treatment option (see table 5): The episode free 
days were increased from 180 days to 200 days, the risk of exacerbation was the 
lowest possible level, the FDA published information about long-term effects of the 
drug and the monthly out-of-expenses were the lowest possible in that set. Hence 
these characteristics define a nearly perfect treatment option for this study. The utility 
score is hence higher than for the other products. The graphical display of this finding 
(see Appendix 1) shows that the utility score distribution for scenario 14 is rightly 
skewed in comparison to the other scenarios. This result can also be underlined 
when looking on the single scores for each scenario (see table 4).  
Table 5: Definition of scenarios for discrete-choice analysis 
Scenario Episode free 
days 
Risk of 
exacerbation 
Information 
available by the FDA 
on long-term effects 
Monthly out-
of-pocket 
expenses 
Scenario 1 
180 to 200 6% of risk No availability $10 
Scenario 2 
180 to 160 16% of risk Available $10 
Scenario 3 
180 to 220 6% of risk No availability $30 
Scenario 4 
180 to 140 6% of risk Available $30 
Scenario 5 
180 to 200 10% of risk No availability $10 
Scenario 6 
180 to 200 6% of risk Available $50 
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Scenario 7 
180 to 140 6% of risk Available $10 
Scenario 8 
180 to 160 6% of risk No availability $10 
Scenario 9 
180 to 160 6% of risk No availability $50 
Scenario 10 
180 to 140 10% of risk No availability $10 
Scenario 11 
180 to 140 16% of risk No availability $50 
Scenario 12 
180 to 200 16% of risk No availability $30 
Scenario 13 
180 to 160 10% of risk Available $30 
Scenario 14 
180 to 200 6% of risk Available $10 
Scenario 15 
180 to 220 10% of risk Available $50 
Scenario 16 
180 to 220 16% of risk Available $10 
 
The scenarios have been stratified in the ones with an improvement in efficacy in 
terms of episode free days (see table 5). The utility distribution for the improved 
efficacy scenarios is still a normal one with scores above or equal to 7 out of 10 
around 50% to 60% and scores above or equal to 8 around 30% (see Appendix A1 
and table 4). However there are also possible outliers in terms of score distributions 
in the population in this sub analysis for scenarios 3 and 12: 47.6% of caregivers 
rated the scenario 3 with a score 7 or higher and 21.4% 8 or better whereas 38.1% of 
individuals rated the utility for scenario 12 with 7 or better and 21.4% with 8 or better. 
One possible explanation could be found when looking on the scenario definitions: 
For scenario 3 no information on long-term effects would be available for a medium 
price of $30, this could support the findings of the conjoint analysis that the expenses 
and the information availability have also a high impact on the scoring of the utility. 
For scenario 12 the product attributes are worsened a step more with the highest 
possible risk of exacerbation, no availability of information by the FDA and a medium 
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price. The results for the utility scores for the scenarios with a worse outcome on 
episode free days is not that clear. There are some scenarios which have a lower 
rating score on both defined thresholds but there are also other scenarios with nearly 
the same mean outcome. One possible explanation for this finding is that the study 
participants trade off desirable attributes (such as improvement of episode free days) 
against undesirable ones (such as high out-of-pocket expenses), and assessing 
which attributes are most important in determining the patient preferences for one 
regimen over another. This finding would support the use of conjoint analysis in such 
studies in comparison to simple utility rating scores. 
 
Correlation and learning effects 
From a theoretical point of view the product attributes have a significant influence on 
the preferences derived from the conjoint analysis [11]. This could also be shown in a 
recent paper [9] for this dataset. Also when thinking about a utility rating score there 
should be some explanatory variables which drive the study respondents to choose 
the utility levels they have reported. To have the highest possible comparability 
between preferences and utilities derived from a conjoint analysis and a rating score 
the same econometric model, a random-effects probit model, was applied. Beyond 
the attributes also socio-economic as well as interrelations between variables were 
included in the ranking score calculations. However, it turned out that there are no 
significant explanatory variables for the high and low score groups, which are driving 
the score estimation (see table 8). One possible explanation could be one of the 
general criticisms on that approach that the utility score is not related to any decision 
and hence not related to any attribute evaluation. Therefore there is no theoretical 
basis with which the results could be interpreted as cardinal utility values. 
The correlations between the scenario decisions, which is assumed to be based on 
the treatment attributes, and the utility scores for the same scenarios could maybe 
anyway show a correlation between each other. Another possible correlation could 
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exist between scenario decisions and any of the later on done scenario evaluations. 
This could be explained by the fact that caregivers are showing a positive learning 
curve about the attribute levels and could maybe rate the scenarios later on in a 
different way than the others.  
The possible interrelation between the scenario decision and the utility score was first 
analyzed. Interestingly only the decisions for scenario 2, 7 and 15 had a significant 
influence on the utility score estimation of the same scenario (see Appendix A2). The 
next step to verify that the treatment attributes are the main driver in this scenario for 
the utility score was to run a random-effect probit model. It turned out that the 
attribute FREEDAYS as well as EXPENSES are statistically highly significant (see 
table 7). Furthermore it can be derived from that exercise that there is collinearity 
between the attributes INFORMATION and EXACERBATION. This could be due to 
the fact that individuals interpret the information from the FDA as part of the side 
effects, or vice versa. Hence just for scenario 2 it could be proofed that caregivers 
specified their utility score according their discrete choice decision, which was based 
on the attributes of the treatment [9].  
Table 7: Random effects probit model for the final utility estimations (Independent variable: Utilities for 
scenarios 2, 7 and 15 derived from score). Interrelations between the variables EXACERBATION and 
INFORMATION and hence these were not taken into account. 
Variable Coefficient Standard error z P>|z| 
FREEDAYS -.0620*** .0159 -3.91 .000 
EXPENSES .0673* .0220 3.07 .002 
CONSTANT 9.3027*** 2.4548 3.79 .000 
Number of observations 126    
Chi² (2) 19.46    
Prob > chi² 0.0001  Rightly 
predicted: 
.7302 
   * (**, ***) Coefficient different from zero with an error probability of 5% (1%, 0.1%). 
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The second correlation analyzes was to find a proof for the learning effect between 
the different scenarios i and the utility score estimations for scenario 1+i (with 
i=1,…16). Some findings propose that the learning curve assumption could hold (see 
Appendix A2), whereas the attributes of the treatment option would not have any 
significant effect on it. Scenario 6, for example, has a significant impact on the utility 
estimations for scenarios 9, 10, 11 and 14. Additionally the decision for scenario 7 
and scenario 8 had both a significant impact on the utility scores 9 and 11. 
Furthermore scenario 12 influences utility scores 13 and 15 and scenario decision 13 
has an influence on score 14. These findings could be interpreted as a learning effect 
between the utility score and the scenario decisions made before. The explanation 
why this finding was not found in more scenarios could maybe be explained by the 
fatigue effect, which means that the individuals were getting bored by the decisions. 
The final correlation analyzes was done to find a correlation between the scenario 
decision i and the scenario decisions 1+i (with i=1,…16). This means it was assumed 
to find a learning effect between the different scenarios each individual had to decide 
on (see Appendix A3). The first 4 scenario decisions had each at least a statistically 
significant impact on the following question. Scenario 1 had additionally an influence 
on scenario 4 and 5, whereas scenario 2 had an additional impact on scenarios 4, 5 
and 6. Scenario 3 had a statistically significant influence on questions 4,5 and also 
13. Also the scenarios 6, 7, 8, 9, 10, 11 and 12 had at least a statistically significant 
impact on the next scenario. Interestingly the first 4 questions had each a direct 
impact on their next decision but not the scenarios 5 onwards. This finding could be 
interpreted that the learning effect at the beginning of the decision process was 
maybe more interesting for the individuals and hence they started to interpret the 
next scenario in relation to the last one but after 4 scenarios they started already to 
be bored and considered their learning just for some of the scenarios.
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Discussion and Conclusion 
This study has investigated patient preferences derived from a utility rating score and 
analyzed the relation between scores and preferences derived from conjoint analysis. 
Additionally the interrelation between the scenario decision derived from the conjoint 
analysis and the utility score was analyzed.  
It turns out that the influence of the product attributes on the score rating was 
statistically not significant. Even in the three scenarios where it could be shown that 
the attributes have a statistically significant influence two of the four attributes 
showed collinearity between each others and hence only the attributes episode free 
days and EXPENSES had an influence. This finding indicates that there is strong 
evidence suggesting that the treatment attributes don’t go along with a utility score. 
This speaks in favor of the validity of conjoint analysis as a method for measuring 
preferences for various treatment options defined by different attributes. 
Findings of the correlation analyzes could be interpreted as a learning effect between 
the utility score and the scenario decisions made before. Overall the fatigue effect of 
the 16 scenario decisions on the utility score estimations could be more important 
than the learning effect. However, a learning effect between the discrete-choice 
scenarios i and 1+i at the beginning of the decision process could be interpreted that 
individuals were more interested in the study at the beginning and hence they started 
to interpret the next scenario in relation to the last one but after 4 scenarios they 
started already to be bored and considered their learning just for some of the 
scenarios. 
The utility scores derived for each scenario were relatively stable and lying between 
a value of 7.095 and 7.929. Only for one scenario the mean utility was estimated 
higher whereas the explanation for this outlier could be very easily found in the 
characteristics of that treatment option: The characteristics of this scenario defines a 
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nearly perfect treatment option for this study and hence the utility score is higher than 
for the other products.  
Of course the utility score could be applied for studies where just the overall utility for 
a given treatment or similar is of interest, but as far as the product attributes are of 
particular interest for the utility estimation, conjoint analysis should be used. 
Additional studies should be done to analyze the link between utilities derived from 
SF-36 or similar and preferences derived from a conjoint analysis. Especially in that 
case it could be interesting to see the interrelations when the product attributes would 
be defined similar to the SF-36 attributes and their levels.  
The impact on economic evaluations, namely cost-utility analysis, depends strongly 
on the purpose of the study and the level of view. If the study is investigated for a 
micro-view dependent on various attributes the preferences derived from a conjoint 
analysis could be the first choice whereas the utilities derived from a utility score 
could be used for a macro-view where just the overall utility for various treatments 
and/or events are of interest.  
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Appendix 
Appendix A1: Distributions, frequencies and a plotted normal distribution for the 16 utility scores 
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Appendix A2: Learning curve analyzes between discrete-choice decision and utility estimation scores - Pearson’s correlation for the 16 scenarios 
 Utility 1 Utility 2 Utility 3 Utility 4 Utility 5 Utility 6 Utility 7 Utility 8 Utility 9 Utility 10 Utility 11 Utility 12 Utility 13 Utility 14 Utility 15 Utility 16 
Scenario 1 -.122 -.066 -.069 -.094 -.078 -.011 -.077 -.159 -.188 -.075 -.107 -.087 -.0.88 -.061 -.009 -.023 
Scenario 2  -.396** -.284 -.242 -.064 -.074 -.219 -.072 -.090 -.204 -.024 -.078 .052 -.016 .006 -.123 
Scenario 3   -.191 -.003 -.026 -.049 -.121 -.198 -.232 -.062 -.152 -.130 -.082 -.033 -.016 -.177 
Scenario 4    .016 -.010 .030 .003 -.052 -.109 -.006 .021 -.184 .019 .072 .070 -.214 
Scenario 5     -.030 -.129 -.195 -.162 -.238 -.113 -.131 -.186 -.082 -.043 -.005 -.243 
Scenario 6      -.298 -.182 -.300 -.346* -.324* -.367* -.164 -.303 -.525** -.276 -.195 
Scenario 7       .138 -.206 -.314* -.068 -.331* -.074 -.185 -.233 -.093 -.053 
Scenario 8        -.158 -.308* -.169 -.322* -.155 -.237 -.302 -.209 -.194 
Scenario 9         .089 .158 .154 .188 .138 .030 .166 .142 
Scenario 10          .202 .167 .258 .189 .047 .208 .207 
Scenario 11           .066 .174 .151 .003 .114 .241 
Scenario 12            -.255 -.308* -.222 -.310* -.173 
Scenario 13             -.289 -.448** -.284 -.038 
Scenario 14              -.030 -.166 -.277 
Scenario 15               -.350* -.280 
Scenario 16                -.033 
* (**) Coefficient different from zero with an (2-tailed) error probability of 5% (1%) 
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Appendix A3: Learning-curve analyzes between the different scenarios - Pearson’s correlation for the 16 scenarios 
 Scenario 
1 
Scenario 
2 
Scenario 
3 
Scenario 
4 
Scenario 
5 
Scenario 
6 
Scenario 
7 
Scenario 
8 
Scenario 
9 
Scenario 
10 
Scenario 
11 
Scenario 
12 
Scenario 
13 
Scenario 
14 
Scenario 
15 
Scenario 
16 
Scenario 1  .608** .300 .400** .428** .263 .213 -.150 -.062 -.035 -.050 246. -.108 .062 .200 .021 
Scenario 2   .340* .312* .525** .319* -.091 -.246 -.102 -.057 -.082 .257 -.178 .102 .230 .257 
Scenario 3    .633** .701** .033 .213 -.177 -.014 -.116 -.167 .021 -.362* .207 -.067 -.278 
Scenario 4     .798** -.033 .085 -.132 .062 -.087 -.125 .053 -.271 .155 .050 -.283 
Scenario 5      .166 .033 -.224 -.145 -.082 -.117 .108 -.253 .145 .078 -.125 
Scenario 6       .203 .231 .469** .425** .263 .109 .383* -.184 .427** .404** 
Scenario 7        .535** .264 .149 -.011 -.091 .098 .106 -.085 -.283 
Scenario 8         .424** .233 .092 -.195 .462** -.014 -.023 .012 
Scenario 9          .563** .372* -.252 .336* -.282 -.124 .119 
Scenario 
10 
          .698** -.142 .322* -.563** -.070 .172 
Scenario 
11 
           -.203 .461** -.806** -.100 .021 
Scenario 
12 
            -.075 .252 .364* -.057 
Scenario 
13 
             -.336* .108 .290 
Scenario 
14 
              .124 .066 
Scenario 
15 
               .235 
Scenario 
16 
                
* (**) Coefficient different from zero with an (2-tailed) error probability of 5% (1%) 
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Abstract 
Objectives: To contribute to current discussions about budget impact modeling two different 
approaches for the impact of a new pharmaceutical product were analyzed: firstly considering 
the impact on annual health care expenditures only and secondly additional inclusion of lost 
insurance premiums due to possible early retirement in patients with chronic diseases. 
Methods: The dynamic model calculates the budget impact from two different perspectives: a) 
the impact on health care expenditures and b) on expenditures as well as on health insurance 
revenues due to premiums. The latter approach could especially be useful for patients with 
chronic diseases who have higher probabilities of early retirement. Early retirement rates and 
indirect costs were derived from published data. Health Care premiums were calculated based 
on an average premium and a mean income. Epidemiological input data were obtained from 
literature. Time horizon was 10 years. 
Results: Results in terms of reimbursement decisions of the budget impact analysis varied 
depending on the assumptions made for the insurance premiums, costs and early retirement 
rate. Sensitivity analyses revealed that in extreme cases the decision for accepting a new 
pharmaceutical product would probably be negative using approach a, but positive using 
approach b.  
Conclusions: Depending on the disease and population of interest in a budget impact analysis 
not only the health care expenditures for a health insurance have to be considered but also the 
revenue side for an insurance due to retirement should be included. 
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Introduction 
The use of economic evaluation in determining resource allocation is well established in a 
number of health services [1]. There is growing recognition that a comprehensive economic 
assessment of a new health care intervention at the time of launch requires both cost-
effectiveness analysis (CEA) and a budget impact analysis (BIA).  
BIA for new pharmaceutical products provides estimates of the likely impact of the new drug on 
healthcare decision-makers short and longer-term annual budgets. It is an essential part of a 
comprehensive economic assessment of a new pharmaceutical product and is increasingly 
required [1], along with CEA, before national or local formulary approval and/or reimbursement.  
National regulatory agencies such as the National Institute for Clinical Excellence (NICE) in 
England and Wales [3], the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia 
[4], the Co-ordinating OFFICE for Health Technology Assessment in Canada [5], the French 
Transparency Committee [6] and the Pharmaceutical Benefits Board in Sweden [7] as well as 
managed care organizations (MCOs) in the USA, now require that companies submit estimates 
of both the cost-effectiveness and the likely impact of the new health care interventions on 
national or health plan budgets to support the reimbursement or formulary inclusion [8]. 
Standard methods for performing and presenting the results of CEAs are well accepted [3], the 
same progress has not been made for BIAs [9]. Several factors, which are not generally needed 
for CEA, should be part of a comprehensive BIA including the size of the treated population, 
incidence and prevalence estimations, market penetration rates for the new drug as well as for 
the main comparators. A review of the recent literature indicates that there are only a limited 
number of published budget impact analyses [10] and these vary greatly in the methods used.  
It is recommended that a comprehensive approach to budget impact estimation be adopted, 
with the results being presented from both a societal perspective as well as from more limited 
perspectives depending on the needs of the decision maker. 
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Recently, Trueman and colleagues have proposed an initial framework for standardization of 
BIAs [8].  
This paper analysis the potential impact of early retirement on health care payer’s annual 
budgets due to a chronic and progressing disease such as diabetes mellitus. The study is first 
based on a theoretical analysis before a hypothetical new product in diabetes treatment is 
applied. 
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Materials and Methods 
The budget of a health care payer like the social insurance payers in Germany or the private 
ones in the US, for instance, are mainly dependent on their expenses as well as their revenues 
[11]. The expenses are mainly dependent on the development of the diseases of the insureds 
and the related costs whereas the revenue is highly influenced by the premium an insured is 
paying. Once an insured is being (early) retired the real amount paid for premiums are much 
lower in comparison to the premiums when an insured is working full-time due to the lower 
income. 
The following paragraph is showing the theoretical impact of early retirement as well as the 
impact of the drug price on the equilibrium equation for a general health insurance. The step 
after is to analyze a hypothetical example with a diabetes population. 
 
Methods 
The cost of illness, including the treatment costs as well as the complication costs due to a 
given disease, is the main driver on the health care payer budgets. The calculation of the cost of 
illness comprises the direct costs for complications (CoC) and the treatment costs (CoT) for the 
given diseases i in the years t, respectively (with i=1,.., N and t=1;…;T). The costs of illness 
(CoI) for n patients are calculated according to the following equation E1: 
 
(E1) ( )
= =
⋅+=
N
i
T
t
iitit nCoTCoCCoI
1 1
 
 
Additionally it is assumed that the number of complications c as well as the severity s of these 
are the drivers for the CoC and the market share MSA, with an influence of price pA+1, as well as 
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the price pA for the drugs A (A=1,…,Z) are the drivers for the CoI. Furthermore the numbers of 
patients p treated in the disease population i is mainly dependent on the prevalence ip and 
incidence ii of the disease as well as the mortality rates mi within that population. Hence 
equation E1 can be rewritten as 
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The revenue side R of a health care payer balance sheet is driven by the premiums h the n 
insureds are paying. 
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Assuming that the income Y of the insureds are influencing the real cash flow h of the revenue 
side and the mortality rates have an impact on the number of insureds, equation E3 can be 
rewritten as following 
 
(E4) ( ) ( )
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Due to the nature of some diseases early retirement is widely spread in some population parts 
[12]. Retirement r as a whole as a significant influence on the income Y of that population. 
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Assuming that no other factors have an impact on the income level equation E4 can be adapted 
to E5 
 
(E5) ( )( ) ( )
=
⋅=
T
t
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For social insurance based systems such as the German health care system, the insurance 
companies are mainly non-profit organizations (with the exception of the private companies). 
Hence the premiums for the insureds are in an equilibrium (without a need for an increase) if the 
revenue of the payers is equal to the costs of these. Assuming that there is only one health care 
payer in a given country equations E2 and E5 represent the equilibrium of the health care payer 
company: 
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To simplify the interpretation of E6 this is rewritten to equation E7 
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First derivations with respect to retirement r and the drug price p for a new product c are as 
follows 
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Equation E8 shows the following: When the retirement rate r changes (∂ r), the income is also 
changed and this could be assumed to be negative. This means that retirement is assumed to 
have a negative impact on the income Y. When the retirement rate r is increasing the real 
income will be decreased. The second part of equation E8 is showing the impact of income Y on 
the premium function h, which could be positive: Due to the higher income it is assumed that the 
real amount of premiums is increasing, when assuming such a health care system as the one in 
Germany. 
In equation E9 it is analyzed in which way a new product with price pi has an influence on the 
insurance equilibrium equation E7. The number of patients n is decreasing the right-hand side 
of the equilibrium function E7 due to the sign of the first derivative. Additionally the costs of 
treatment CoTA are of interest, whereas the sign here is mainly dependent on the price level as 
well as on the market share MSA (first two parts in the bracket). Furthermore the change in 
costs of treatment and market share of the comparators of product A, namely A-1 and A+1, 
have an influence on the sign of that first derivative. Hence the sign of this equation is not clear 
and has to be analyzed case wise. The sign is mainly dependent on the price level of the 
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comparator drugs and their market share. These findings are only valid for the case 1≠A  and 
ZA ≠ . One special case is an innovative product without any comparators (A=1). Then the 
costs of treatment are changing with the price (increase) and the whole first derivative with 
respect to pi is becoming negative. This would than have an influence on the revenue side 
which has to be increased to still fulfill the equilibrium criteria in equation E7.  
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Results 
After the theoretical analysis of an impact of early retirement and also price changes for a 
product A, a hypothetical comparison follows. The market i is assumed to be the one for type 2 
diabetes mellitus patients. The comparison is based on the epidemiological finding of the 
UKPDS, where glycaemic control was analyzed with the options of diet, sulphonylurea, 
metformin and insulin therapy [13]. 
 
In a usual budget impact analysis two scenarios are compared, which are usually assumed to 
be a world with the new possible treatment option and other available treatments and one 
without that new option, which is usually the environment of the current market. The market 
share is changed due to the fact that this new option will be available on the market. 
For this hypothetical analysis it is assumed that a pharmaceutical company will develop an 
innovation of a so-called oral antidiabetic (OADs), which is assumed to be more effective in 
comparison to the OADs currently available on the market. However the insulins are still the 
state of the art after OADs are no more working properly in the patients in terms of HbA1c 
adjustment.  
For the following analysis direct costs for various diabetes complications were derived from 
O’Brien et al. [14] whereas it was directly assumed that these US data could also be valid for 
the German circumstance (see table 1).  
Table 1: Base assumptions for the three budget impact scenarios 
Parameter Base Case Scenario Best Case Scenario Worst Case Scenario 
Average yearly income 
(€) * 
35,517 35,517 35,517 
Average yearly income 
lost due to early 
retirement (€) 
14,207 14,207 14,207 
Retirement rate for 
current Tx (%) 
5.0 5.0 5.0 
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Retirement rate for 
current Tx and new 
option (%) 
5.0 2.5 7.5 
Premium (percentage of 
yearly income) * 
14.0 14.0 14.0 
Covered population - in 
both arms 
83,000,000 83,000,000 83,000,000 
Number of treated 
patients * 
107,070 107,070 107,070 
Prevalence (%) * 6.45 6.45 6.45 
Incidence per year 1,000 500 2,000 
* in the “Current Tx” and “Current Tx & NEW option” arm 
Prevalence data as well as early retirement data were derived from literature [12]. The main 
assumptions for this analysis are summarized in table 2. 
Table 2: Diabetes related complication costs derived from literature 
Cost item Costs per event (€) Source 
Hypoglycemia 384 Diabetes Care; 1995; 18(11) (16) 
Retinopathy / Macular edema 71 O’Brien et al.; Diabetes Care 1998 
(14) 
Blindness in one eye 4,365 O’Brien et al.; Diabetes Care 1998 
(14) 
Cataract 2,250 Internal expert assumption 
Micro- / Macroalbuminuria 78 O’Brien et al.; Diabetes Care 1998 
(14) 
End-stage renal disease 77,735 O’Brien et al.; Diabetes Care 1998 
(14) 
Neuropathy 273 O’Brien et al.; Diabetes Care 1998 
(14) 
Peripheral arterial disease 6,867 DRG handbook (17) 
Diabetic foot syndrome 3,421 O’Brien et al.; Diabetes Care 1998 
(14) 
Myocardial infarction 34,597 O’Brien et al.; Diabetes Care 1998 
(14) 
Heart failure 12,038 DRG handbook (17) 
Angina pectoris 3,102 O’Brien et al.; Diabetes Care 1998 
(14) 
Stroke 50,858 O’Brien et al.; Diabetes Care 1998 
(14) 
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Assumed complication rates derived from UKPDS 33 are summarized in Appendix A1. The 
market for diabetes was assumed to consist just with insulin drugs and oral antidiabetics 
(OADs). The efficacy of the hypothetical new option on the market was assumed to be 20% 
better in terms of outcomes in comparison to the standard OADs. Hence the following two 
scenarios are analyzed: The world without the new option with the market share distribution in 
the following way. 38% of patients are getting a subcutaneous insulin and the rest of the treated 
patients are getting the OADs. All other patient groups treated with any other possibility are not 
taken into account.  
 
The market share over time is changed in the way that the insulin market will have a market 
share of 40% after 1 year and hence the OAD market is declining by that amount. The world 
with the new option has the same starting point for the insulin and the OADs, whereas the new 
option is assumed to have no market share at all. The following three scenarios (defined on the 
view of a pharmaceutical company) are analyzed for the comparator world including the 
hypothetical new treatment (table 3): 
 
• Base Case: The retirement rate was assumed to be 5% for both scenarios. 
Additionally the following market shares were assumed: 
o Market share for insulin after 4 years 45% 
o Market share for OADs after 8 years: 10% 
o Market share for the new option after 8 years: 45% 
• Best Case: The retirement rate was assumed to be 2.5% for both scenarios. 
Additionally the following market shares were assumed: 
o Market share for insulin after 4 years 30% 
o Market share for OADs after 8 years: 0% 
o Market share for the new option after 8 years: 70% 
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• Worst Case: The retirement rate was assumed to be 7.5% for both scenarios. 
Additionally the following market shares were assumed: 
o Market share for insulin after 4 years 50% 
o Market share for OADs after 8 years: 31% 
o Market share for the new option after 8 years: 19% 
Table 3: Market share for the three possible treatments over time for the three budget impact scenarios 
Market Share Current Market Share Target Market Share 
(Base / Best / Worst) 
Time to reach the target 
Insulin: Current Tx * 38 40 1 
OADs: Current Tx * 62 60 1 
Insulin: Current Tx + new 
option 
38 45 / 30 / 50 4 
OADs: Current Tx + new 
option 
62 10 / 0 / 31  8 
New option 0 45 / 70 / 19  8 
* Assumption: fixed market in terms of scenarios 
 
The price for subcutaneous insulin was assumed to be €89, for the OADs €286 (see table 4). 
The base, best and worst case analyses were run within some stratification groups for the 
incidence cases and drug costs for the new option (see table 1). 
Table 4: Yearly drug costs in Euro for the three pharmaceutical treatment options on the market 
Cost item (€; yearly) Base Case Scenario Best Case Scenario Worse Case Scenario 
Insulin 286 286 286 
Oral antidiabetics 
(OADs) 
89 89 89 
New option 1,000 500 1,500 
 
The budget impact for the base case analysis, 1,000 incident cases and drug costs of €500 
ranged from €58,860,034 (best case) to €99,108,673 (base case) cumulative after 10 years 
(Appendix A3). Assuming that the premium assumption of 14% p.a. was an equilibrium of the 
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costs and the expenses (see equation E7) the difference between the yearly premiums of the 
world with and without the hypothetical new drug ranged between 0.0034 and 0.0122, which 
was a proportional difference between 2.3% and 8.9% after 10 years. It turned out that the 
direction of the difference of the yearly premiums and the budget impact result would influence 
the decision makers in the same way. The new treatment option is not only more effective and 
has a positive impact on the health care payer’s budget (in terms of cost reduction) but has also 
a reduction in the yearly premiums as a result due to the improvement of the early retirement 
rate. This conclusion can also be drawn for the third sensitivity analyses (drug price: €1,500). 
The only scenario where the hypothetical new drug is dominant in terms of budget impact and 
premium change is the analysis with an assumed drug price of €500.  
The second analysis was done by taking the same assumptions as before but changing the 
incidence rate from 1,000 new cases per year to 500 new cases per year. For the base case 
analysis (drug costs €500) it can be seen that the budget impact is negative which means that 
the current treatment possibilities (insulin and OADs) are cheaper than the current treatment 
inclusive the hypothetical new treatment (see Appendix A2). But when reviewing the yearly 
premiums based on the early retirement rate and the costs per year, the decision maker should 
go with the new treatment due to lower yearly premiums, between 0.0046 (proportional: 2.6%) 
and 0.0167 (proportional: 10.0%). The same conclusion can be drawn when doing the analysis 
for a yearly drug price per patient of €1,500. Interestingly the influence on the decision maker is 
changed when including a drug price for the hypothetical new option to €500. With that price the 
budget impact is improved in terms of cost reduction with the new treatment as well as a lower 
premium per year. 
The third analysis was run for the three scenarios described above and an incidence rate of 
2,000 new cases per year (see Appendix A4). Also for this stratification analysis it turns out that 
the impact of the early retirement rate is much higher for the yearly premium calculations than 
for the budget impact. The budget impact would speak in favor of the new hypothetical 
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treatment for a price of €500 but not for the other two price options whereas the premiums 
calculations would always lead to the conclusion that the new treatment should be reimbursed 
by the health care payer. 
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Discussion 
The dependency of health care payers on their revenue based on the premiums paid by their 
insured population and the costs mainly influenced by the cost of complications and the costs of 
treatment (pharmaceutical costs) was analyzed within a budget impact modeling framework. 
Across the ISPOR members of the Budget Impact Analysis Task Force there is no consensus at 
this time point whether the revenue side of the health care payers should also be taken into 
account within a budget impact analysis [15]. This study shows the theoretical implications of a 
new product if a change in the early retirement rate could be expected for a new product due to 
a higher efficacy in comparison to the standard treatment. The product price as well as the 
assumptions for the early retirement rate can change the equilibrium of a revenue-cost premium 
calculation for a health care payer as was derived in a theoretical model. Additionally a 
hypothetical comparison in diabetes patients was undergone. The theoretical results could be 
proofed by this study. Some assumptions had to be done, for instance on the levels of the drug 
prices, incidence and prevalence rates as well as the event rates for some complications which 
were derived from a well-known study [13]. In general it turned out that the premium differences 
were always in favor of the new option opportunity, which could be the fact due to the 
assumption of a 20% better influence on the complications. The negative influence of the new 
option in terms of budget impact was highly dependent on the assumed drug price and the early 
retirement rate. 
The weakness of this theoretical study can be seen in the following points. The premium 
calculations are usually based on all diseases and hence on all patients as well as on the 
disease free population of the given health care payer. Within this hypothetical example it was 
assumed that only one disease area (diabetes) was of interest when analyzing the impact on 
the annual premiums. It was assumed that the impact of all other diseases as well as the impact 
of the healthy population is hold constant when comparing the two worlds of interest: Current 
treatment versus current treatment and new option. Additionally the impact of these groups was 
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assumed to be constant over time and hence no new drugs would enter the market for other 
diseases where a health care payer could benefit from. Also, the early retirement rates were 
held constant over time, which means the impact of the new drug option and also the higher 
early retirement risk with a higher age, was not taken into account. Within such a circumstance 
it can be seen that a new drug with a higher efficacy could lead to a benefit for the health care 
payer with two possibilities: On the one hand the new treatment possibility could reduce the 
costs and could hence result in an improvement for the budget impact for some scenarios and 
on the other hand, which could go along with the budget impact argument, the new drug could 
lower the complication rates which would reduce the complication costs and the early retirement 
rate. The last point could lead to a possible decrease in the annual premiums due to a higher 
revenue. This last option is not just valid assuming a non-profit health care payer like the social 
insurance companies in Germany, for instance, but also for private insurances looking for 
profits. For the latter ones the profitability would increase by the difference of the annual 
premiums. 
The here suggested framework should be taken into account if there is any possibility of early 
retirement reduction due to a more effective treatment possibility. It is recommended that 
sensitivity analysis are not only done with the costs but also with the market share over time as 
well as with the incidence rates, based on epidemiological data. Further empirical research on 
the influence of premiums and costs on the decision making process is given a favorable 
opinion. 
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Appendix 
Appendix A1: Cumulative diabetes complication rates derived from UKPDS 33 [13] for the world with and without the new option (“Current treatment” vs “Current 
treatment & NEW option”). The complication rates are reported for the hypothetical diabetes cohort of 107,070 at year 0 (see assumptions). 
Complication “Current treatment” 
 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 
Hypoglycemia 2,478 5,274 7,257 8,861 10,060 11,087 11,782 12,331 12,772 10,649 
Ophthalmic 
disorders 
(retinopathy, 
macular edema, 
blindness, 
cataract) 
12,376 23,052 31,963 39,641 46,598 52,785 58,389 63,589 68,376 72,850 
Kidney system 
(Micro-, 
macroalbuminuria, 
end-stage renal 
disease) 
4,835 9,460 14,175 18,373 22,431 26,438 30,321 33,827 37,141 39,842 
Nerve system 
(neuropathy, 
peripheral arterial 
disease, diabetic 
foot syndrome) 
4,613 9,042 13,571 18,124 22,578 26,874 30,963 35,442 40,158 44,560 
Cardiovascular 
system 
3,094 5,8839 8,651 11,365 14,038 16,619 19,142 21,398 23,713 26,014 
Mortality 5,845 11,442 16,574 21,279 25,920 30,118 34,032 37,834 41,378 44,782 
Complication “Current treatment & NEW option” 
 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 
Hypoglycemia 2,831 5,092 6,999 8,688 9,876 10,945 11,672 12,279 12,915 13,387 
Ophthalmic 
disorders 
(retinopathy, 
11,513 21,403 29,638 36,704 43,064 48,508 53,467 58,008 62,184 66,029 
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macular edema, 
blindness, 
cataract) 
Kidney system 
(Micro-, 
macroalbuminuria, 
end-stage renal 
disease) 
4,460 8,687 12,996 16,872 20,596 24,244 27,787 30,993 34,047 36,536 
Nerve system 
(neuropathy, 
peripheral arterial 
disease, diabetic 
foot syndrome) 
4,286 8,348 12,423 16,517 20,489 24,283 27,819 31,706 35,773 39,509 
Cardiovascular 
system 
2,931 5,564 8,180 10,722 13,251 15,717 18,076 20,173 22,303 24,419 
Mortality 5,484 10,732 15,519 19,979 24,438 28,395 32,121 35,824 39,304 42,625 
 
Appendix A2: Budget Impact and premium differences for the three scenarios (base, best worse case) and for the corresponding (new option) cost groups for the 
incidence group 1,000 patients per year. Budget Impact as well as premium differences are “Current Tx” vs “Current Tx & NEW”.  
Incidence per year: 1,000 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 
New option costs: 
€500 
          
Budget Impact: Base 
Case 
8,8847,518 14,172,088 24,553,377 36,123,442 44,348,912 49,426,880 60,670,863 70,756,833 85,102,459 99,108,673 
Budget Impact:  Best 
Case 
4,968,733 5,573,514 12,102,680 20,062,508 24,303,277 25,193,357 32,636,192 38,612,245 49,164,357 58,860,034 
Budget Impact:  Worse 
Case 
7,117,511 12,480,246 20,742,754 29,663,493 36,593,758 41,611,688 50,223,934 58,257,157 68,769,327 79,312,377 
Premium difference (%): 
Base Case 
0.0013 (0.1) 0.0028 (1.8) 0.0045 (2.9) 0.0059 (3.7) 0.0071 (4.4) 0.0082 (5.1) 0.0089 (5.7) 0.0091 (5.9) 0.0088 (6.0) 0.0085 (6.1) 
Premium difference (%): 
Best Case 
0.0024 (1.6) 0.0045 (3.0) 0.0068 (4.4) 0.0087 (5.5) 0.0103 (6.5) 0.0118 (7.5) 0.0127 (8.2) 0.0129 (8.6) 0.0126 (8.8) 0.0122 (8.9) 
Premium difference (%): 
Worse Case 
0.0001 (0.1) 0.0008 (0.5) 0.0016 (1.0) 0.0022 (1.3) 0.0027 (1.6) 0.0032 (2.2) 0.0036 (2.3) 0.0036 (2.3) 0.0035 (2.3) 0.0034 (2.3) 
New option costs: 
€1,000 
          
Budget Impact: Base 
Case 
-11,008,614 -26,070,717 -36,652,501 -46,415,326 -59,806,876 -76,750,125 -88,377,410 -101,887,136 -112,177,201 -123,979,141 
Budget Impact:  Best 
Case 
-28,738,462 -62,164,812 -89,744,421 -115,808,158 -145,612,915 -179,171,899 -207,231,445 -237,830,339 -265,435,969 -295,744,857 
Budget Impact:  Worse 
Case 
-513,781 -2,483,397 -1,653,996 -279,004 -1,012,490 -3,858,233 -3,693,205 -4,510,308 -3,303,420 -2,494,335 
Premium difference (%): 
Base Case 
0.0013 (0.8) 0.0028 (1.8) 0.0045 (2.8) 0.0059 (3.6) 0.007 (4.3) 0.0081 (5.0) 0.0088 (5.6) 0.0089 (5.8) 0.0087 (5.9) 0.0084 (6.0) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0068 (4.3) 0.0086 (5.4) 0.0102 (6.4) 0.0116 (7.4) 0.0125 (8.1) 0.0127 (8.5) 0.0125 (8.7) 0.0121 (8.8) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0008 (0.5) 0.0015 (0.9) 0.0021 (1.3) 0.0026 (1.6) 0.0031 (1.9) 0.0034 (2.1) 0.0035 (2.2) 0.0034 (2.2) 0.0032 (2.2) 
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New option costs: 
€1,500 
          
Budget Impact: Base 
Case 
-30,339,519 -65,342,035 -96,289,765 -126,743,112 -161,193,055 -199,692,095 -233,500,675 -269,927,604 -304,028,352 -340,790,018 
Budget Impact:  Best 
Case 
-61,920,432 -128,931,651 -190,022,909 -249,467,842 -312,759,498 -380,302,119 -443,174,072 -509,669,424 -574,607,786 -644,072,811 
Budget Impact:  Worse 
Case 
-7,619,847 -16,475,553 -22,482,132 -28,010,518 -35,849,128 -46,093,119 -53,685,334 -62,674,272 -69,947,658 -78,024,111 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0045 (2.8) 0.0059 (3.6) 0.007 (4.3) 0.0081 (5.0) 0.0088 (5.6) 0.0089 (5.8) 0.0087 (5.9) 0.0084 (6.0) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0068 (4.3) 0.0086 (5.4) 0.0102 (6.4) 0.0116 (7.4) 0.0125 (8.1) 0.0127 (8.5) 0.013 (8.7) 0.0121 (8.8) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0008 (0.9) 0.0015 (0.9) 0.0021 (1.3) 0.0026 (1.6) 0.0032 (1.9) 0.0034 (2.1) 0.0035 (2.2) 0.0034 (2.2) 0.0032 (2.2) 
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Appendix A3: Budget Impact and premium differences for the three scenarios (base, best worse case) and for the corresponding (new option) cost groups for the 
incidence group 500 patients per year. Budget Impact as well as premium differences are “Current Tx” vs “Current Tx & NEW”.  
Incidence per year: 500 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 
New option costs: 
€500 
          
Budget Impact: Base 
Case 
8,322,292 13,200,602 22,984,763 33,912,459 41,579,302 46,191,844 56,745,854 66,153,332 79,673,949 92,831,737 
Budget Impact:  Best 
Case 
4,602,027 4,602,027 10,534,066 17,851,526 21,533,668 21,958,321 28,711,182 34,008,745 43,735,848 52,583,097 
Budget Impact:  Worse 
Case 
6,592,285 11,508,759 19,174,141 27,452,510 33,824,149 38,376,653 46,298,925 53,653,656 63,340,817 73,035,440 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0045 (2.8) 0.0059 (3.6) 0.007 (4.3) 0.0081 (5.0) 0.0088 (5.6) 0.0089 (5.8) 0.0087 (5.9) 0.0084 (6.0) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0068 (4.3) 0.0086 (5.4) 0.0102 (6.4) 0.0116 (7.4) 0.0127 (8.1) 0.0127 (8.5) 0.0125 (8.7) 0.0121 (8.8) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0008 (0.5) 0.0015 (0.9) 0.0021 (1.3) 0.0026 (1.6) 0.0031 (1.9) 0.0034 (2.1) 0.0035 (2.2) 0.0034 (2.2) 0.0032 (2.2) 
New option costs: 
€1,000 
          
Budget Impact: Base 
Case 
-11,008,614 -26,002,120 -36,453,342 -46,000,992 -58,886,072 -74,875,789 -85,752,481 -98,107,186 -107,540,589 -118,061,822 
Budget Impact:  Best 
Case 
-28,738,462 -62,009,423 -89,219,944 -114,620,480 -143,187,163 -174,725,971 -200,609,303 -228,166,314 -252,589,238 -278,662,119 
Budget Impact:  Worse 
Case 
-513,781 -2,475,995 -1,671,224 -372,342 -1,138,886 -3,899,416 -3,928,150 -4,886,497 -4,197,019 -3,927,155 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0046 (2.8) 0.0061 (3.7) 0.0076 (4.4) 0.0092 (5.3) 0.0104 (6.0) 0.0111 (6.4) 0.0115 (6.6) 0.0117 (6.8) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0069 (4.3) 0.009 (5.5) 0.011 (6.6) 0.013 (7.7) 0.0148 (8.7) 0.0158 (9.3) 0.0164 (9.7) 0.0167 (10.0) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0008 (0.5) 0.0016 (0.9) 0.0022 (1.3) 0.0028 (1.6) 0.0036 (2.0) 0.0041 (2.3) 0.0044 (2.4) 0.0046 (2.5) 0.0046 (2.6) 
 Stefan Walzer – 5 Essays in Health Economics 130 
New option costs: 
€1,500 
          
Budget Impact: Base 
Case 
-30,339,519 -65,176,386 -95,691,990 -125,316,374 -158,228,845 -194,222,406 -225,112,588 -257,516,882 -287,111,454 -318,067,899 
Budget Impact:  Best 
Case 
-61,920,432 -128,613,390 -188,842,320 -246,641,851 -307,072,176 -370,175,648 -427,511,437 -486,532,420 -542,643,841 -600,872,385 
Budget Impact:  Worse 
Case 
-7,619,847 -16,434,486 -22,363,688 -27,761,139 -35,280,174 -44,879,832 -51,912,247 -60,000,445 -66,465,838 -73,438,798 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0046 (2.8) 0.0061 (3.7) 0.0076 (4.4) 0.0092 (5.3) 0.0104 (6.0) 0.0111 (6.4) 0.0115 (6.6) 0.0117 (6.8) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0069 (4.3) 0.009 (5.5) 0.1104 (6.6) 0.0131 (7.7) 0.0148 (8.7) 0.0158 (9.3) 0.0164 (9.7) 0.0167 (10.0) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0008 (0.5) 0.0016 (0.9) 0.0022 (1.3) 0.0028 (1.6) 0.0036 (2.0) 0.0041 (2.3) 0.0044 (2.4) 0.0046 (2.5) 0.0046 (2.6) 
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Appendix A4: Budget Impact and premium differences for the three scenarios (base, best worse case) and for the corresponding (new option) cost groups for the 
incidence group 2,000 patients per year. Budget Impact as well as premium differences are “Current Tx” vs “Current Tx & NEW”.  
Incidence per year: 2,000 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 
New option costs: 
€500 
          
Budget Impact: Base 
Case 
8,322,292 13,257,513 23,383,676 35,108,597 43,824,505 49,633,878 63,022,311 75,854,974 94,961,295 114,606,698 
Budget Impact:  Best 
Case 
4,443,507 4,616,994 10,797,333 18,752,795 23,205,302 24,427,551 33,547,884 41,626,652 56,276,813 70,652,998 
Budget Impact:  Worse 
Case 
6,592,285 11,561,286 19,479,943 28,324,620 35,467,645 40,931,960 50,784,880 60,506,065 73,878,853 87,937,344 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0043 (2.8) 0.0053 (3.5) 0.006 (4.1) 0.0065 (4.6) 0.0066 (5.0) 0.0062 (5.1) 0.0057 (5.0) 0.0051 (5.0) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0044 (2.9) 0.0065 (4.2) 0.0079 (5.3) 0.0088 (6.1) 0.0094 (6.9) 0.0095 (7.3) 0.009 (7.5) 0.0082 (7.4) 0.0074 (7.4) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0007 (0.5) 0.0014 (0.9) 0.0019 (1.2) 0.0022 (1.4) 0.0025 (1.7) 0.0025 (1.9) 0.0024 (1.9) 0.0021 (1.8) 0.0019 (1.8) 
New option costs: 
€1,000 
          
Budget Impact: Base 
Case 
-11,008,614 -26,002,120 -36,453,342 -46,000,992 -58,886,072 -74,875,789 -85,752,481 -98,107,186 -107,540,589 -118,061,822 
Budget Impact:  Best 
Case 
-28,738,462 -62,009,423 -89,219,944 -114,620,480 -143,187,163 -174,725,971 -200,609,303 -228,166,314 -252,589,238 -278,662,119 
Budget Impact:  Worse 
Case 
-513,781 -2,475,995 -1,671,224 -372,342 -1,138,886 -3,899,416 -3,928,150 -4,886,497 -4,197,019 -3,927,155 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0046 (2.8) 0.0061 (3.7) 0.0076 (4.4) 0.0092 (5.3) 0.0104 (6.0) 0.0111 (6.4) 0.0115 (6.6) 0.0117 (6.8) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0069 (4.3) 0.009 (5.5) 0.011 (6.6) 0.0131 (7.7) 0.0148 (8.7) 0.0158 (9.3) 0.0164 (9.7) 0.0167 (10.0) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0016 (0.9) 0.0022 (1.3) 0.0028 81.6) 0.0036 (2.0) 0.0041 (2.3) 0.0044 (2.3) 0.0044 (2.4) 0.0046 (2.5) 0.0046 (2.6) 
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New option costs: 
€1,500 
          
Budget Impact: Base 
Case 
-30,339,519 -65,176,386 -95,691,990 -125,316,374 -158,228,845 -194,222,406 -225,112,588 -257,516,882 -287,111,454 -318,067,899 
Budget Impact:  Best 
Case 
-61,920,432 -128,613,390 -188,842,320 -246,641,852 -307,072,176 -370,175,648 -427,511,437 -486,511,437 -542,643,841 -600,872,385 
Budget Impact:  Worse 
Case 
-7,920,432 -16,434,486 -22,363,688 -27,761,139 -35,280,174 -44,897,832 -51,912,247 -60,000,445 -66,465,838 -73,438,798 
Premium difference (%): 
Base Case 
0.0013 (0.9) 0.0028 (1.8) 0.0046 (2.8) 0.0061 (3.7) 0.0076 (4.4) 0.0092 (5.3) 0.0104 (6.0) 0.0111 (6.4) 0.0115 (6.6) 0.0117 (6.8) 
Premium difference (%): 
Best Case 
0.0023 (1.6) 0.0045 (2.9) 0.0069 (4.3) 0.009 (5.5) 0.011 (6.6) 0.0131 (7.7) 0.0148 (8.7) 0.0158 (9.3) 0.0164 (9.7) 0.0167 (10.0) 
Premium difference (%): 
Worse Case 
0.0001 (0.0) 0.0008 (0.5) 0.0016 (0.9) 0.0022 (1.3) 0.0028 (1.6) 0.0036 (2.0) 0.0041 (2.3) 0.0044 (2.4) 0.0046 (2.5) 0.0046 (2.6) 
 
 Stefan Walzer – 5 Essays in Health Economics 133 
 
 
 
Chapter 8: Conclusion 
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The conclusion is confined to a brief discussion of possible impacts of the results on 
medical decision-making. The first essay on a new approach of cost-effectiveness 
analysis provides an interesting and empirically testable model framework. It has to 
be discussed whether it is worthwhile to assume the time trend of the discount rate to 
use this approach or whether it is easier and more pragmatic to stick with the current 
framework. In a hypothetical example the model showed differences between the 
current approach and the approach suggested in the essay whereas this has first to 
be proven by a face-to-face comparison of a real world cost-effectiveness project. 
Essays two and three show the preferences of caregivers for an asthma treatment for 
their children aged 4 years and younger. The general criticisms about discrete choice 
experiments are also valid here: The results should only be interpreted with the 
attributes used for the study. Additionally the relatively small sample size should be 
considered as a crucial element, whereas the robustness of the analyses was tested 
by a Monte-Carlo simulation. These findings show once again that the conjoint 
analysis is a useful tool for economic evaluation studies and could be improving the 
decision-making process by understanding the preferences of the consumers or their 
caregivers. Essay four shows that there could be some learning effects, especially for 
some of the scenarios but overall it could not be proven that there is a significant 
effect of it on the results. This finding should be taken into consideration when 
designing and implementing or evaluating conjoint analyses. 
The final paper gives a new framework for budget impact modeling: Decision makers, 
such as health maintenance organizations, hospitals or insurances are more and 
more interested in the budget impact of a new product. The approach suggested in 
the essay is the first one where not only the cost side but also the revenue side of 
such a decision-maker is taken into consideration. The early retirement rate has an 
impact on the real premium an individual is paying and hence a new product, which 
is decreasing early retirement, could even be worthwhile when it is more costly in 
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comparison to other products. That approach shows that not only the cost side but 
also the revenue side should be taken into account in such (Budget Impact) models. 
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